<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
    <channel>
        <title>MedWorm: Migraine</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 7000 RSS medical sources are combined and output via different filters. This feed contains the latest news and research in the Migraine category.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=migraines+migraine+headches+headache&kid=51&t=Migraine&f=c]]></link>
        <lastBuildDate>Fri, 01 Mar 2013 14:43:02 +0100</lastBuildDate>
        <item>
            <title>How Migraine Develops</title>
            <link>http://www.medworm.com/index.php?rid=7115686&amp;cid=c_51_58_f&amp;fid=30179&amp;url=http%3A%2F%2Fwww.sciencemag.org%2Fcontent%2F339%2F6123%2F1009.5.full%3Frss%3D1</link>
            <description>Migraine is a common medical disorder. Unfortunately, how and why migraine headache is initiated is unclear. Karatas et al. (p. 1092) now describe a signaling pathway between stressed neurons and … [Read more] (Source: This Week in Science)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>This Week in Science</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7115686</comments>
            <pubDate>Fri, 01 Mar 2013 05:30:33 +0100</pubDate>
            <guid isPermaLink="false">7115686</guid>        </item>
        <item>
            <title>[Report] Spreading Depression Triggers Headache by Activating Neuronal Panx1 Channels</title>
            <link>http://www.medworm.com/index.php?rid=7115669&amp;cid=c_51_58_f&amp;fid=30175&amp;url=http%3A%2F%2Fwww.sciencemag.org%2Fcontent%2F339%2F6123%2F1092.full%3Frss%3D1</link>
            <description>Migraine results from a sequence of events starting from stressed cortical neurons and leading to the trigeminal nucleus.Authors: Hulya Karatas, Sefik Evren Erdener, Yasemin Gursoy-Ozdemir, Sevda Lule, Emine Eren-Koçak, Zümrüt Duygu Sen, Turgay Dalkara (Source: Science: Current Issue)</description>
            <author>Science: Current Issue</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7115669</comments>
            <pubDate>Fri, 01 Mar 2013 05:30:27 +0100</pubDate>
            <guid isPermaLink="false">7115669</guid>        </item>
        <item>
            <title>White matter integrity affected by depressive symptoms in migraine without aura: a tract‐based spatial statistics study</title>
            <link>http://www.medworm.com/index.php?rid=7113824&amp;cid=c_51_37_f&amp;fid=33609&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1002%252Fnbm.2924</link>
            <description>Previous studies have proven that migraine and depression are bidirectionally linked. However, few studies have investigated white matter (WM) integrity affected by depressive symptoms in patients suffering from migraine without aura (MWoA). Forty patients with MWoA were divided into two groups according to their self‐rating depression scale (SDS) score in the present study, including 20 in the SDS (+) (SDS &amp;gt; 49) group and 20 in the SDS (−) (SDS ≤ 49) group. Forty healthy participants were also recruited as the control group. Tract‐based spatial statistics analyses with multiple diffusion tensor imaging‐derived indices [fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), axial diffusivity (AD)] were employed collectively to investigate WM integr...</description>
            <author>NMR in Biomedicine</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7113824</comments>
            <pubDate>Fri, 01 Mar 2013 00:17:49 +0100</pubDate>
            <guid isPermaLink="false">7113824</guid>        </item>
        <item>
            <title>Migraine Increased in Celiac and Inflammatory Bowel DiseaseMigraine Increased in Celiac and Inflammatory Bowel Disease</title>
            <link>http://www.medworm.com/index.php?rid=7113269&amp;cid=c_51_25_f&amp;fid=36061&amp;url=http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F780039%3Fsrc%3Drsshttp%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F780039%3Fsrc%3Drss</link>
            <description>Although the higher incidence in celiac patients was partly expected, the increase among patients with inflammatory bowel disease was a surprise.  Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)</description>
            <author>Medscape Neurology and Neurosurgery Headlines</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7113269</comments>
            <pubDate>Thu, 28 Feb 2013 21:18:32 +0100</pubDate>
            <guid isPermaLink="false">7113269</guid>        </item>
        <item>
            <title>A costly revolution for a subgroup of patients with metastatic melanoma</title>
            <link>http://www.medworm.com/index.php?rid=7112838&amp;cid=c_51_12_f&amp;fid=31732&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fbjd.12238</link>
            <description>This report is based on the cut‐off date of 19 December 2011. Patients with previously untreated stage IV or unresectable stage III BRAF (V600)‐mutated melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg m−2 intravenously every 3 weeks). Patients were stratified according to American Joint Committee on Cancer stage. The primary endpoint was investigator‐assessed progression‐free survival (PFS) and was analysed by intention to treat. Safety was assessed per protocol.
Findings  Of the 733 patients screened, 250 were randomly assigned to receive either dabrafenib (187 patients) or dacarbazine (63 patients). Median PFS was 5·1 months for dabrafenib and 2·7 months for dacarbazine, with a hazard ratio of 0·30...</description>
            <author>British Journal of Dermatology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7112838</comments>
            <pubDate>Thu, 28 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7112838</guid>        </item>
        <item>
            <title>A case of lipoprotein glomerulopathy with thrombotic microangiopathy due to malignant hypertension</title>
            <link>http://www.medworm.com/index.php?rid=7115374&amp;cid=c_51_47_f&amp;fid=32574&amp;url=http%3A%2F%2Fwww.biomedcentral.com%2F1471-2369%2F14%2F53</link>
            <description>Conclusion:
We report on a rare case of TMA probably due to malignant hypertension in LPG. Early lipid-lowering and antihypertensive treatment may improve outcome. The pathophysiologic relationship between LPG and TMA should be investigated further. (Source: BMC Nephrology)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>BMC Nephrology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7115374</comments>
            <pubDate>Thu, 28 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7115374</guid>        </item>
        <item>
            <title>This Week in Science</title>
            <link>http://www.medworm.com/index.php?rid=7115621&amp;cid=c_51_58_f&amp;fid=30175&amp;url=http%3A%2F%2Fwww.sciencemag.org%2Fcontent%2F339%2F6123%2Ftwis.full%3Frss%3D1</link>
            <description>Interfering Single Electrons | Prevention or Repair | A Hidden Black Hole? | Controlling Magnetic Noise | How Migraine Develops | No Leader to Follow | Mastering Meiosis | Genetic Clues to Meningioma | A Role for IFN-ɛ | Improving Nanowire Photovoltaics | Coo Coo | A Mossy Veil | The Regulatory Genome | Dissecting Disaggregation | Mighty Male Microbes | Double Whammy (Source: Science: Current Issue)</description>
            <author>Science: Current Issue</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7115621</comments>
            <pubDate>Thu, 28 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7115621</guid>        </item>
        <item>
            <title>Headache and suicide. A historical note - Maggioni F, Maggioni G, Mainardi F, Zanchin G.</title>
            <link>http://www.medworm.com/index.php?rid=7110929&amp;cid=c_51_46_f&amp;fid=34959&amp;url=http%3A%2F%2Fwww.safetylit.org%2Fcitations%2Findex.php%3Ffuseaction%3Dcitations.viewdetails%26citationIds%5B%5D%3Dcitjournalarticle_392390_18</link>
            <description>[Abstract unavailable]
Language: Eng... (Source: SafetyLit: All (Unduplicated))</description>
            <author>SafetyLit: All (Unduplicated)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7110929</comments>
            <pubDate>Wed, 27 Feb 2013 23:30:53 +0100</pubDate>
            <guid isPermaLink="false">7110929</guid>        </item>
        <item>
            <title>Underestimated phenomena: Higher cortical dysfunctions during migraine aura - Petrusic I, Zidverc-Trajkovic J, Podgorac A, Sternic N.</title>
            <link>http://www.medworm.com/index.php?rid=7110887&amp;cid=c_51_46_f&amp;fid=34959&amp;url=http%3A%2F%2Fwww.safetylit.org%2Fcitations%2Findex.php%3Ffuseaction%3Dcitations.viewdetails%26citationIds%5B%5D%3Dcitjournalarticle_392377_5</link>
            <description>IntroductionAura occurs in 20-30% of patients with migraine. Some descriptions of aura go far beyond the most frequent visual and sensory symptoms, suggesting the involvement of different cortical areas. The aim of this prospective study was to evaluate th... (Source: SafetyLit: All (Unduplicated))</description>
            <author>SafetyLit: All (Unduplicated)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7110887</comments>
            <pubDate>Wed, 27 Feb 2013 23:30:52 +0100</pubDate>
            <guid isPermaLink="false">7110887</guid>        </item>
        <item>
            <title>Limited Access: Rural Communities Struggle to Find Internet Providers</title>
            <link>http://www.medworm.com/index.php?rid=7111722&amp;cid=c_51_65_f&amp;fid=38988&amp;url=http%3A%2F%2Fwww.washingtonpost.com%2Flocal%2Flimited-access-rural-communities-struggle-to-find-internet-providers%2F2013%2F02%2F26%2Fba1acbbc-8025-11e2-a671-0307392de8de_story.html</link>
            <description>Associated Press article via The Washington Post, (DC), tells why finding reliable and affordable Internet can be a headache in rural areas. (Source: News stories via the Rural Assistance Center)</description>
            <author>News stories via the Rural Assistance Center</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7111722</comments>
            <pubDate>Wed, 27 Feb 2013 06:00:00 +0100</pubDate>
            <guid isPermaLink="false">7111722</guid>        </item>
        <item>
            <title>Vascular ERK mediates migraine‐related sensitization of meningeal nociceptors</title>
            <link>http://www.medworm.com/index.php?rid=7113258&amp;cid=c_51_25_f&amp;fid=33584&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1002%252Fana.23873</link>
            <description>Abstract
Objective:To examinechanges in the response properties of meningeal nociceptors that might lead to migraine pain and examine endogenous processes that could play a role in mediating them using a clinically relevant model of migraine triggering, namely infusion of the NO donor nitroglycerin (NTG).
Methods:Single unit recordings made in the trigeminal ganglion of rats were used to test changes in the activity and mechanosensitivity of meningeal nociceptors in response to administration of the migraine triggerNTGor anotherNO donor SNAPat doses relevant to the human model of migraine headache.Immunohistochemistry and pharmacological manipulations were used to investigate the possible role of meningeal vascular signaling inmediating the responses of meningeal nociceptors to NO.
Results...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Annals of Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7113258</comments>
            <pubDate>Wed, 27 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7113258</guid>        </item>
        <item>
            <title>An Important Phase 2 in MigraineAn Important Phase 2 in Migraine</title>
            <link>http://www.medworm.com/index.php?rid=7104613&amp;cid=c_51_26_f&amp;fid=36062&amp;url=http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F779523%3Fsrc%3Drsshttp%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F779523%3Fsrc%3Drss</link>
            <description>A new phase 2 trial evaluates the safety and efficacy of gabapentin enacarbil for migraine prophylaxis.  Medscape Neurology (Source: Medscape Today Headlines)</description>
            <author>Medscape Today Headlines</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7104613</comments>
            <pubDate>Tue, 26 Feb 2013 15:44:59 +0100</pubDate>
            <guid isPermaLink="false">7104613</guid>        </item>
        <item>
            <title>Cerebral venous system and anatomical predisposition to high‐altitude headache</title>
            <link>http://www.medworm.com/index.php?rid=7108858&amp;cid=c_51_25_f&amp;fid=33584&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1002%252Fana.23796</link>
            <description>ObjectiveAs inspired oxygen availability falls with ascent to altitude, some individuals develop high‐altitude headache (HAH). We postulated that HAH results when hypoxia‐associated increases in cerebral blood flow occur in the context of restricted venous drainage, and is worsened when cerebral compliance is reduced. We explored this hypothesis in 3 studies.
MethodsIn high‐altitude studies, retinal venous distension (RVD) was ophthalmoscopically assessed in 24 subjects (6 female) and sea‐level cranial magnetic resonance imaging was performed in 12 subjects ascending to 5,300m. Correlation of headache burden (summed severity scores [0–4] ≤24 hours from arrival at each altitude) with RVD, and with cerebral/cerebrospinal fluid (CSF)/venous compartment volumes, was sought. In a se...</description>
            <author>Annals of Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7108858</comments>
            <pubDate>Tue, 26 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7108858</guid>        </item>
        <item>
            <title>Sinonasal disease in polyostotic fibrous dysplasia and McCune–Albright Syndrome</title>
            <link>http://www.medworm.com/index.php?rid=7112982&amp;cid=c_51_16_f&amp;fid=34280&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1002%252Flary.23758</link>
            <description>ConclusionsSinonasal involvement of fibrous dysplasia in PFD/MAS is common. Symptoms are usually few and mild, and disease progression occurs primarily in young subjects. Concomitant endocrinopathy is associated with disease severity, but not progression. (Source: The Laryngoscope)</description>
            <author>The Laryngoscope</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7112982</comments>
            <pubDate>Tue, 26 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7112982</guid>        </item>
        <item>
            <title>Panic Disorder and MigrainePanic Disorder and Migraine</title>
            <link>http://www.medworm.com/index.php?rid=7103174&amp;cid=c_51_26_f&amp;fid=36062&amp;url=http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F779108%3Fsrc%3Drsshttp%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F779108%3Fsrc%3Drss</link>
            <description>How closely are panic disorder and migraine linked? This comprehensive review summarizes current epidemiologic, mechanistic, and clinical research on their association.  Headache (Source: Medscape Today Headlines)</description>
            <author>Medscape Today Headlines</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7103174</comments>
            <pubDate>Tue, 26 Feb 2013 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">7103174</guid>        </item>
        <item>
            <title>Health Tip: When Your Child Has a Headache</title>
            <link>http://www.medworm.com/index.php?rid=7103788&amp;cid=c_51_26_f&amp;fid=37163&amp;url=http%3A%2F%2Fwww.nlm.nih.gov%2Fmedlineplus%2Fnews%2Ffullstory_134329.html</link>
            <description>Follow these tips to soothe the pain
Source: HealthDay
Related MedlinePlus Pages: Children's Health, Headache (Source: MedlinePlus Health News)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>MedlinePlus Health News</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7103788</comments>
            <pubDate>Mon, 25 Feb 2013 12:00:00 +0100</pubDate>
            <guid isPermaLink="false">7103788</guid>        </item>
        <item>
            <title>How to halt migraines without prescription drugs</title>
            <link>http://www.medworm.com/index.php?rid=7107492&amp;cid=c_51_91_f&amp;fid=36976&amp;url=http%3A%2F%2Fwww.naturalnews.com%2F039254_migraines_remedies_allergens.html</link>
            <description>If you are one of the 30 million Americans that suffers from occasional or frequent migraine headaches, then you already know how debilitating and excruciatingly painful this condition can be. But rather than simply manage the symptoms when they appear by taking powerful... (Source: NaturalNews.com)</description>
            <author>NaturalNews.com</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7107492</comments>
            <pubDate>Mon, 25 Feb 2013 06:00:00 +0100</pubDate>
            <guid isPermaLink="false">7107492</guid>        </item>
        <item>
            <title>Aripiprazole for the treatment of pediatric bipolar I disorder: a 30‐week, randomized, placebo‐controlled study</title>
            <link>http://www.medworm.com/index.php?rid=7102716&amp;cid=c_51_172_f&amp;fid=27197&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fbdi.12042</link>
            <description>Conclusions:  Aripiprazole 10 mg/day and 30 mg/day were superior to placebo and generally well tolerated in pediatric subjects with bipolar I disorder up to 30 weeks. Despite the benefits of treatment, completion rates were low in all treatment arms. (Source: Bipolar Disorders)</description>
            <author>Bipolar Disorders</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7102716</comments>
            <pubDate>Mon, 25 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7102716</guid>        </item>
        <item>
            <title>Randomized controlled trial of trigeminal nerve stimulation for drug-resistant epilepsy</title>
            <link>http://www.medworm.com/index.php?rid=7103834&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F9%2F786%3Frss%3D1</link>
            <description>Conclusions:
This study provides preliminary evidence that eTNS is safe and may be effective in subjects with DRE. Side effects were primarily limited to anxiety, headache, and skin irritation. These results will serve as a basis to inform and power a larger multicenter phase III clinical trial.

Classification of evidence:
This phase II study provides Class II evidence that trigeminal nerve stimulation may be safe and effective in reducing seizures in people with DRE. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7103834</comments>
            <pubDate>Mon, 25 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7103834</guid>        </item>
        <item>
            <title>Isolated ocular flutter</title>
            <link>http://www.medworm.com/index.php?rid=7103846&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F9%2F867%3Frss%3D1</link>
            <description>A previously healthy 30-year-old man presented with gradually worsening oscillopsia 2 weeks after an unusual headache; there was ocular flutter on examination (video on the Neurology&amp;reg; Web site at www.neurology.org) without other findings. Brain MRI was unremarkable. CSF showed mild pleocytosis (11 cells/mm3), but no evidence of active viral infections (herpes simplex virus, cytomegalovirus, varicella-zoster virus, Epstein-Barr virus, human herpesvirus 6, and measles). Serum antiganglioside antibodies (including anti-GQ1b antibody) were negative. The symptom resolved without treatment within 4 weeks. Ocular flutter is rare and may be isolated, although it is usually accompanied by generalized myoclonus or truncal ataxia.1,2 Brainstem (omnipause neurons in the paramedian pontine reticula...</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7103846</comments>
            <pubDate>Mon, 25 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7103846</guid>        </item>
        <item>
            <title>Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society</title>
            <link>http://www.medworm.com/index.php?rid=7103847&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F9%2F868%3Frss%3D1</link>
            <description>Editors&amp;rsquo; Note: Dr. Mauskop reviews the literature on the use of butterbur extract for migraine prophylaxis and concludes that it has the potential for serious toxicity. Authors Holland et al. disagree with Dr. Mauskop's interpretation. Dr. Sethi, in response to Drs. Stone and Edwards' &quot;Trick or treat? Showing patients with functional (psychogenic) motor symptoms their physical signs,&quot; airs the difficulty, which most neurologists can relate to, of discussing a psychogenic diagnosis with a patient. Dr. Tfelt-Hansen calls attention to an error in the classification of evidence in the American Academy of Neurology guideline on episodic migraine prevention by Silberstein et al. The authors concur and an erratum appears in this issue. Megan Alcauskas, MD, and Robert C. Griggs, MD (Source: ...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7103847</comments>
            <pubDate>Mon, 25 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7103847</guid>        </item>
        <item>
            <title>Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society</title>
            <link>http://www.medworm.com/index.php?rid=7103849&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F9%2F869-a%3Frss%3D1</link>
            <description>Peer Carsten Tfelt-Hansen, Glostrup, Denmark: According to the recent American Academy of Neurology (AAN) guideline update, a drug can be recommended as possibly effective for migraine prevention if it had demonstrated efficacy in one Class II study.1 Eight drugs are recommended as possibly effective,1 and there are several drugs for which I would question the evidence. Due to space limitations, I have chosen just one example. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7103849</comments>
            <pubDate>Mon, 25 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7103849</guid>        </item>
        <item>
            <title>Paradoxical presentation of orthostatic headache associated with increased intracranial pressure in patients with cerebral venous thrombosis</title>
            <link>http://www.medworm.com/index.php?rid=7103878&amp;cid=c_51_25_f&amp;fid=33843&amp;url=http%3A%2F%2Fwww.annalsofian.org%2Ftext.asp%3F2013%2F16%2F1%2F85%2F107705</link>
            <description>Jung B Kim, Do-Young Kwon, Moon-Ho Park, Byung-Jo Kim, Kun-Woo ParkAnnals of Indian Academy of Neurology 2013 16(1):85-87Headache is the most common symptom of cerebral venous thrombosis (CVT); however, the detailed underlying mechanisms and characteristics of headache in CVT have not been well described. Here, we report two cases of CVT whose primary and lasting presentation was orthostatic headache, suggestive of decreased intracranial pressure. Contrary to our expectations, the headaches were associated with elevated cerebrospinal fluid (CSF) pressure. Magnetic resonance imaging and magnetic resonance venography showed characteristic voiding defects consistent with CVT. We suggest that orthostatic headache can be developed in a condition of decreased intracranial CSF volume in both intr...</description>
            <author>Annals of Indian Academy of Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7103878</comments>
            <pubDate>Mon, 25 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7103878</guid>        </item>
        <item>
            <title>Spontaneous intracranial hypotension with bilateral subdural hemorrhage: Is conservative management adequate?</title>
            <link>http://www.medworm.com/index.php?rid=7103881&amp;cid=c_51_25_f&amp;fid=33843&amp;url=http%3A%2F%2Fwww.annalsofian.org%2Ftext.asp%3F2013%2F16%2F1%2F94%2F107709</link>
            <description>Mohammed Tauqeer Ahmad, Shahul Hameed, Kei Pin Lin, Kumar M PrakashAnnals of Indian Academy of Neurology 2013 16(1):94-96The aim of this study is to report a case of spontaneous intracranial hypotension complicated by bilateral subdural hemorrhage that resolved with conservative management. A young male presented with severe orthostatic headache associated with dizziness, neck pain and diplopia. Brain imaging revealed characteristic pachymeningeal enhancement and bilateral subdural hemorrhage. Radionuclide cisternography confirmed the Cerebrospinal fluid leak at the cervical 5 and cervical 6 vertebral level. He had clinical and radiological resolution with bed rest, hydration and analgesics and has remained symptom free since then. Spontaneous intracranial hypotension may be complicated by...</description>
            <author>Annals of Indian Academy of Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7103881</comments>
            <pubDate>Mon, 25 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7103881</guid>        </item>
        <item>
            <title>Low-dose propofol alleviates migraines in pediatric ED patients [HEALTH BRIEFS]</title>
            <link>http://www.medworm.com/index.php?rid=7104302&amp;cid=c_51_33_f&amp;fid=32751&amp;url=http%3A%2F%2Faapnews.aappublications.org%2Fcgi%2Fcontent%2Ffull%2F34%2F3%2F2%3Frss%3D1</link>
            <description>(Source: AAP News)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>AAP News</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7104302</comments>
            <pubDate>Mon, 25 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7104302</guid>        </item>
        <item>
            <title>Ambrisentan: Headache and skin eruption in an elderly patient: case report</title>
            <link>http://www.medworm.com/index.php?rid=7096834&amp;cid=c_51_13_f&amp;fid=33942&amp;url=http%3A%2F%2Fwww.ingentaconnect.com%2Fcontent%2Fadis%2Frea%2F2013%2F00000001%2F00001439%2Fart00019</link>
            <description>(Source: Reactions)</description>
            <author>Reactions</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7096834</comments>
            <pubDate>Sun, 24 Feb 2013 06:03:04 +0100</pubDate>
            <guid isPermaLink="false">7096834</guid>        </item>
        <item>
            <title>Fusing Engineering And Mathematical Principles Helps Create Dynamic Brain Models</title>
            <link>http://www.medworm.com/index.php?rid=7091174&amp;cid=c_51_26_f&amp;fid=23292&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2Fmnt%2Fhealthnews%2F%7E3%2FUlL27rNzwKU%2F256644.php</link>
            <description>Models of the human brain, patterned on engineering control theory, may some day help researchers control such neurological diseases as epilepsy, Parkinson's and migraines, according to a Penn State researcher who is using mathematical models of neuron networks from which more complex brain models emerge. &quot;The dual concepts of observability and controlability have been considered one of the most important developments in mathematics of the 20th century,&quot; said Steven J. Schiff, the Brush Chair Professor of Engineering and director of the Penn State Center for Neural Engineering... (Source: Health News from Medical News Today)</description>
            <author>Health News from Medical News Today</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7091174</comments>
            <pubDate>Fri, 22 Feb 2013 08:00:00 +0100</pubDate>
            <guid isPermaLink="false">7091174</guid>        </item>
        <item>
            <title>What Are the Clinical Criteria Justifying Spinal Manipulative Therapy for Neck Pain?— A Systematic Review of Randomized Controlled Trials</title>
            <link>http://www.medworm.com/index.php?rid=7092735&amp;cid=c_51_5_f&amp;fid=28811&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fpme.12041</link>
            <description>ConclusionsThis systematic review highlights the absence of reliable and valid diagnostic protocols to determine the need for spinal manipulation in persons presenting with non‐serious, idiopathic, or whiplash‐associated (grade II) neck pain. Guidelines requiring the reporting of valid diagnostic criteria are needed to improve the quality of RCTs concerning manual therapy. (Source: Pain Medicine)</description>
            <author>Pain Medicine</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7092735</comments>
            <pubDate>Fri, 22 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7092735</guid>        </item>
        <item>
            <title>Contributions of Epidemiology to Our Understanding of Migraine</title>
            <link>http://www.medworm.com/index.php?rid=7093325&amp;cid=c_51_25_f&amp;fid=32225&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fhead.12038</link>
            <description>ConclusionsThis review demonstrates that the descriptive epidemiology of migraine has reached its maturity. The prevalence rates and sociodemographic correlates have been stable across 50 years. These developments justify a shift in efforts to the application of the designs and methods of analytic epidemiology. Retrospective case–control studies followed by prospective cohort studies that test specific associations are likely to enhance our understanding of the predictors of incidence and progression of migraine, subtypes of migraine with differential patterns of onset and course, and specific environmental exposures that may have either causal or provocative influences on migraine etiology. (Source: Headache: The Journal of Head and Face Pain)</description>
            <author>Headache: The Journal of Head and Face Pain</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7093325</comments>
            <pubDate>Fri, 22 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7093325</guid>        </item>
        <item>
            <title>Contraception and Headache</title>
            <link>http://www.medworm.com/index.php?rid=7093326&amp;cid=c_51_25_f&amp;fid=32225&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fhead.12035</link>
            <description>Most women have used at least 1 method of contraception during their reproductive years, with the majority favoring combined oral contraceptives. Women are often concerned about the safety of their method of choice and also ask about likely effects on their pre‐existing headache or migraine and restrictions on using their headache medication.
While there should be no restriction to the use of combined hormonal contraceptives by women with migraine without aura, the balance of risks vs benefits for women with aura are debatable. Migraine with aura, but not migraine without aura, is associated with a twofold increased risk of ischemic stroke, although the absolute risk is very low in healthy, nonsmoking women. Although ethinylestradiol has been associated with increased risk of ischemic st...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Headache: The Journal of Head and Face Pain</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7093326</comments>
            <pubDate>Fri, 22 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7093326</guid>        </item>
        <item>
            <title>Oral Methylergonovine Maleate for Refractory Migraine and Cluster Headache Prevention</title>
            <link>http://www.medworm.com/index.php?rid=7093327&amp;cid=c_51_25_f&amp;fid=32225&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fhead.12033</link>
            <description>(Source: Headache: The Journal of Head and Face Pain)</description>
            <author>Headache: The Journal of Head and Face Pain</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7093327</comments>
            <pubDate>Fri, 22 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7093327</guid>        </item>
        <item>
            <title>Does Ultrasound Guidance Facilitate Facial Botulinum Injections?</title>
            <link>http://www.medworm.com/index.php?rid=7093328&amp;cid=c_51_25_f&amp;fid=32225&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fj.1526-4610.2013.02206.x</link>
            <description>(Source: Headache: The Journal of Head and Face Pain)</description>
            <author>Headache: The Journal of Head and Face Pain</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7093328</comments>
            <pubDate>Fri, 22 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7093328</guid>        </item>
        <item>
            <title>Comment on Headache Following Intracranial Neuroendovascular Procedures</title>
            <link>http://www.medworm.com/index.php?rid=7093329&amp;cid=c_51_25_f&amp;fid=32225&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fj.1526-4610.2013.02272.x</link>
            <description>(Source: Headache: The Journal of Head and Face Pain)</description>
            <author>Headache: The Journal of Head and Face Pain</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7093329</comments>
            <pubDate>Fri, 22 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7093329</guid>        </item>
        <item>
            <title>Sublingual Feverfew/Ginger (LipiGesic M) Reanalysis of Data</title>
            <link>http://www.medworm.com/index.php?rid=7093330&amp;cid=c_51_25_f&amp;fid=32225&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fj.1526-4610.2012.02282.x</link>
            <description>(Source: Headache: The Journal of Head and Face Pain)</description>
            <author>Headache: The Journal of Head and Face Pain</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7093330</comments>
            <pubDate>Fri, 22 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7093330</guid>        </item>
        <item>
            <title>Migraine Relief by Chilis and Other Alternative Medications – Caused by Platelet Inhibition?</title>
            <link>http://www.medworm.com/index.php?rid=7093331&amp;cid=c_51_25_f&amp;fid=32225&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fj.1526-4610.2012.02289.x</link>
            <description>(Source: Headache: The Journal of Head and Face Pain)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Headache: The Journal of Head and Face Pain</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7093331</comments>
            <pubDate>Fri, 22 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7093331</guid>        </item>
        <item>
            <title>Medication Overuse Headache in School‐Aged Children: More Common Than Expected?</title>
            <link>http://www.medworm.com/index.php?rid=7093332&amp;cid=c_51_25_f&amp;fid=32225&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fj.1526-4610.2012.02291.x</link>
            <description>(Source: Headache: The Journal of Head and Face Pain)</description>
            <author>Headache: The Journal of Head and Face Pain</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7093332</comments>
            <pubDate>Fri, 22 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7093332</guid>        </item>
        <item>
            <title>Headache and Suicide. A Historical Note</title>
            <link>http://www.medworm.com/index.php?rid=7093333&amp;cid=c_51_25_f&amp;fid=32225&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fj.1526-4610.2012.02290.x</link>
            <description>(Source: Headache: The Journal of Head and Face Pain)</description>
            <author>Headache: The Journal of Head and Face Pain</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7093333</comments>
            <pubDate>Fri, 22 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7093333</guid>        </item>
        <item>
            <title>Abstracts and Citations</title>
            <link>http://www.medworm.com/index.php?rid=7093334&amp;cid=c_51_25_f&amp;fid=32225&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fhead.12032</link>
            <description>(Source: Headache: The Journal of Head and Face Pain)</description>
            <author>Headache: The Journal of Head and Face Pain</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7093334</comments>
            <pubDate>Fri, 22 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7093334</guid>        </item>
        <item>
            <title>Chronic Migraine</title>
            <link>http://www.medworm.com/index.php?rid=7093335&amp;cid=c_51_25_f&amp;fid=32225&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fhead.12036</link>
            <description>(Source: Headache: The Journal of Head and Face Pain)</description>
            <author>Headache: The Journal of Head and Face Pain</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7093335</comments>
            <pubDate>Fri, 22 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7093335</guid>        </item>
        <item>
            <title>Erratum</title>
            <link>http://www.medworm.com/index.php?rid=7093336&amp;cid=c_51_25_f&amp;fid=32225&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fhead.12044</link>
            <description>(Source: Headache: The Journal of Head and Face Pain)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Headache: The Journal of Head and Face Pain</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7093336</comments>
            <pubDate>Fri, 22 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7093336</guid>        </item>
        <item>
            <title>Is Benign Paroxysmal Vertigo of Childhood a migraine precursor?</title>
            <link>http://www.medworm.com/index.php?rid=7116956&amp;cid=c_51_25_f&amp;fid=35547&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2FPubMed%2F23434307%3Fdopt%3DAbstract</link>
            <description>CONCLUSION: We have observed that the prevalence of migraine in patients that had been diagnosed with BPVC is higher than in the general population, which leads us to propose BPVC as a precursor of migraine during childhood.
    PMID: 23434307 [PubMed - as supplied by publisher] (Source: European Journal of Paediatric Neurology)</description>
            <author>European Journal of Paediatric Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7116956</comments>
            <pubDate>Thu, 21 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7116956</guid>        </item>
        <item>
            <title>The Role of Laboratory Testing in the Evaluation of Headache.</title>
            <link>http://www.medworm.com/index.php?rid=7084500&amp;cid=c_51_22_f&amp;fid=33236&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2FPubMed%2F23419622%3Fdopt%3DAbstract</link>
            <description>Authors: Donohoe CD
    Abstract
    Blood tests have a minor role in headache management and that role is limited to a few secondary headache conditions. In headache, as with any symptom, laboratory tests should be chosen based on solid clues derived from the targeted history and physical examination. A shotgun approach to blood tests that includes rare diseases or those with low local prevalence frequently yields false-positive results, which exposes the patient to the expense, anxiety, and risk inherent in misdiagnosis. Keep it simple and do not forget about spinal fluid.
    PMID: 23419622 [PubMed - as supplied by publisher] (Source: The Medical Clinics of North America)</description>
            <author>The Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084500</comments>
            <pubDate>Thu, 21 Feb 2013 00:00:04 +0100</pubDate>
            <guid isPermaLink="false">7084500</guid>        </item>
        <item>
            <title>The Role of the Physical Examination in the Evaluation of Headache.</title>
            <link>http://www.medworm.com/index.php?rid=7084502&amp;cid=c_51_22_f&amp;fid=33236&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2FPubMed%2F23419621%3Fdopt%3DAbstract</link>
            <description>Authors: Donohoe CD
    Abstract
    The most critical element in headache evaluation is the history. The targeted history differentiates primary from secondary headaches and provides a realistic list of conditions associated with secondary headache. Several of these conditions present with specific physical findings, such as papilledema, Horner's syndrome, or a cranial nerve palsy. The targeted physical examination of the patient with headache takes less than 3 minutes. The ability to recognize a few straightforward clinical findings directs the evaluation in the proper direction.
    PMID: 23419621 [PubMed - as supplied by publisher] (Source: The Medical Clinics of North America)</description>
            <author>The Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084502</comments>
            <pubDate>Thu, 21 Feb 2013 00:00:04 +0100</pubDate>
            <guid isPermaLink="false">7084502</guid>        </item>
        <item>
            <title>Targeted Headache History.</title>
            <link>http://www.medworm.com/index.php?rid=7084504&amp;cid=c_51_22_f&amp;fid=33236&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2FPubMed%2F23419620%3Fdopt%3DAbstract</link>
            <description>Authors: Waldman SD
    Abstract
    The targeted headache history is paramount in the diagnosis of headache and facial pain. Through placing symptoms in categories, a clear picture of the headache diagnosis will begin to emerge. The physical examination yields no positive findings in most patients with headache. Medication overuse headache is emerging as a common reason for inability to control headaches.
    PMID: 23419620 [PubMed - as supplied by publisher] (Source: The Medical Clinics of North America)</description>
            <author>The Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084504</comments>
            <pubDate>Thu, 21 Feb 2013 00:00:04 +0100</pubDate>
            <guid isPermaLink="false">7084504</guid>        </item>
        <item>
            <title>Trigeminal Autonomic Cephalalgias Other than Cluster Headache.</title>
            <link>http://www.medworm.com/index.php?rid=7084486&amp;cid=c_51_22_f&amp;fid=33236&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2FPubMed%2F23419629%3Fdopt%3DAbstract</link>
            <description>Authors: Silberstein SD, Vodovskaia N
    Abstract
    Trigeminal autonomic cephalalgias are short-lasting primary headache disorders associated with autonomic symptoms. Paroxysmal hemicrania is a rare headache disorder similar to cluster headache. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) are unusual headache syndromes typified by a high frequency of severe, brief, unilateral attacks that usually occur in the distribution of the trigeminal nerve. SUNCT is a subtype of SUNA in which both conjunctival injection and tearing are present. SUNA differs from SUNCT in that autonomic symptoms are less prominent.
    PMID: 23419629 [PubMed - ...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>The Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084486</comments>
            <pubDate>Thu, 21 Feb 2013 00:00:03 +0100</pubDate>
            <guid isPermaLink="false">7084486</guid>        </item>
        <item>
            <title>Headache Pain of Ear, Nose, Throat, and Sinus Origin.</title>
            <link>http://www.medworm.com/index.php?rid=7084488&amp;cid=c_51_22_f&amp;fid=33236&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2FPubMed%2F23419628%3Fdopt%3DAbstract</link>
            <description>This article provides the clinician with a concise road map for the evaluation of painful conditions of the ear, nose, sinuses, and throat that may be responsible for headache.
    PMID: 23419628 [PubMed - as supplied by publisher] (Source: The Medical Clinics of North America)</description>
            <author>The Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084488</comments>
            <pubDate>Thu, 21 Feb 2013 00:00:03 +0100</pubDate>
            <guid isPermaLink="false">7084488</guid>        </item>
        <item>
            <title>Pain of Ocular and Periocular Origin.</title>
            <link>http://www.medworm.com/index.php?rid=7084490&amp;cid=c_51_22_f&amp;fid=33236&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2FPubMed%2F23419627%3Fdopt%3DAbstract</link>
            <description>Authors: Waldman CW, Waldman SD, Waldman RA
    Abstract
    Most diseases of the eye and periocular regions that cause blindness are relatively painless. Headache pain of ocular and periocular origin represent a special challenge to the clinician. For patients with ocular and periocular pain that is unrelated to primary eye disease, identification and treatment of the painful condition usually become the responsibility of the clinician.
    PMID: 23419627 [PubMed - as supplied by publisher] (Source: The Medical Clinics of North America)</description>
            <author>The Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084490</comments>
            <pubDate>Thu, 21 Feb 2013 00:00:03 +0100</pubDate>
            <guid isPermaLink="false">7084490</guid>        </item>
        <item>
            <title>Managing and Treating Tension-type Headache.</title>
            <link>http://www.medworm.com/index.php?rid=7084492&amp;cid=c_51_22_f&amp;fid=33236&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2FPubMed%2F23419626%3Fdopt%3DAbstract</link>
            <description>Authors: Freitag F
    Abstract
    Although tension-type headache is ubiquitous, only a relatively small percentage of the population has these headaches occurring with sufficient frequency and severity to cause them to seek out medical attention. This small group, however, may have substantial impact from their disease on productivity and quality of life. Assessment of the headaches includes other headache disorders and coexisting diseases that may contribute to the process. Treatment is optimized by appropriate use of acute medications and preventive treatments that may include drugs in the antidepressant classes along with nonpharmacologic modalities and other alternative treatments, such as biofeedback, manual therapy, and use of botulinum toxin type A injections.
    PMID: 23419626 [...</description>
            <author>The Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084492</comments>
            <pubDate>Thu, 21 Feb 2013 00:00:03 +0100</pubDate>
            <guid isPermaLink="false">7084492</guid>        </item>
        <item>
            <title>Managing and Treating Headache of Cervicogenic Origin.</title>
            <link>http://www.medworm.com/index.php?rid=7084494&amp;cid=c_51_22_f&amp;fid=33236&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2FPubMed%2F23419625%3Fdopt%3DAbstract</link>
            <description>This article reviews and summarizes the points of contention, historical significance, differential diagnosis, and treatments for CGH. This information will be of benefit to clinicians treating patients with this condition and assist providers in reviewing the literature and treatments for CGH.
    PMID: 23419625 [PubMed - as supplied by publisher] (Source: The Medical Clinics of North America)</description>
            <author>The Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084494</comments>
            <pubDate>Thu, 21 Feb 2013 00:00:03 +0100</pubDate>
            <guid isPermaLink="false">7084494</guid>        </item>
        <item>
            <title>Imaging in the Evaluation of Headache.</title>
            <link>http://www.medworm.com/index.php?rid=7084496&amp;cid=c_51_22_f&amp;fid=33236&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2FPubMed%2F23419624%3Fdopt%3DAbstract</link>
            <description>This article reviews when and how to use imaging for headaches, and what abnormalities may be found on these studies.
    PMID: 23419624 [PubMed - as supplied by publisher] (Source: The Medical Clinics of North America)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>The Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084496</comments>
            <pubDate>Thu, 21 Feb 2013 00:00:03 +0100</pubDate>
            <guid isPermaLink="false">7084496</guid>        </item>
        <item>
            <title>Factors That Cause Concern.</title>
            <link>http://www.medworm.com/index.php?rid=7084498&amp;cid=c_51_22_f&amp;fid=33236&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2FPubMed%2F23419623%3Fdopt%3DAbstract</link>
            <description>Authors: Abrams BM
    Abstract
    Headaches can be benign or life threatening but, with careful attention to the details described in this article, the correct diagnosis and treatment can be arrived at in many cases. Modern imaging techniques have taken the guesswork out of many conditions but a high index of suspicion and attention to red flags helps avoid potential adverse outcomes in headache encounters in a high proportion of cases.
    PMID: 23419623 [PubMed - as supplied by publisher] (Source: The Medical Clinics of North America)</description>
            <author>The Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084498</comments>
            <pubDate>Thu, 21 Feb 2013 00:00:03 +0100</pubDate>
            <guid isPermaLink="false">7084498</guid>        </item>
        <item>
            <title>Medication Overuse Headaches.</title>
            <link>http://www.medworm.com/index.php?rid=7084482&amp;cid=c_51_22_f&amp;fid=33236&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2FPubMed%2F23419631%3Fdopt%3DAbstract</link>
            <description>Authors: Abrams BM
    Abstract
    Overuse of any class of drugs, Triptans, ergots, opioids, simple, or combination analgesics used to treat acute headaches, especially migraine, can lead to the development of medication overuse headache. People suffering from primary headache types, such as migraine or tension-type headache, are at higher risk to develop chronic headache following the overuse of acute headache drugs. Treatment of medication overuse headache requires withdrawal as an initial step, coincident initiation of preventive treatment, a multidisciplinary setting, and includes education of patients.
    PMID: 23419631 [PubMed - as supplied by publisher] (Source: The Medical Clinics of North America)</description>
            <author>The Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084482</comments>
            <pubDate>Thu, 21 Feb 2013 00:00:02 +0100</pubDate>
            <guid isPermaLink="false">7084482</guid>        </item>
        <item>
            <title>Is osteopathic manipulative treatment effective in migraine?</title>
            <link>http://www.medworm.com/index.php?rid=7083727&amp;cid=c_51_8_f&amp;fid=38483&amp;url=http%3A%2F%2Fwww.journalofosteopathicmedicine.com%2Farticle%2FPIIS1746068913000096%2Fabstract%3Frss%3Dyes</link>
            <description>Discussion: This preliminary data, even though not completed, showed a significant difference between OMT group and the other two, suggesting that the OMT may be considered an efficient procedure in the management of patients with migraine. (Source: International Journal of Osteopathic Medicine)</description>
            <author>International Journal of Osteopathic Medicine</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7083727</comments>
            <pubDate>Wed, 20 Feb 2013 19:30:55 +0100</pubDate>
            <guid isPermaLink="false">7083727</guid>        </item>
        <item>
            <title>EFSA’s Extremely Flimsy Safety argument for Aspartame</title>
            <link>http://www.medworm.com/index.php?rid=7083733&amp;cid=c_51_8_f&amp;fid=39068&amp;url=http%3A%2F%2Fanh-europe.org%2FEFSAs-Extremely-Flimsy-Safety-argument-for-Aspartame</link>
            <description>European Food Safety Authority gets out the whitewash yet again (Source: Alliance for Natural Health)</description>
            <author>Alliance for Natural Health</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7083733</comments>
            <pubDate>Wed, 20 Feb 2013 15:29:52 +0100</pubDate>
            <guid isPermaLink="false">7083733</guid>        </item>
        <item>
            <title>CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?</title>
            <link>http://www.medworm.com/index.php?rid=7083837&amp;cid=c_51_13_f&amp;fid=32560&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fbph.12129</link>
            <description>Summary
The neuropeptide calcitonin gene‐related peptide (CGRP) is reported to play an important role in migraine. It is expressed throughout the trigeminovascular system. Antagonists targeting the CGRP receptor have been developed and have shown efficacy in clinical trials for migraine. However, no CGRP antagonist is yet approved for treating this condition. The molecular composition of the CGRP receptor is unusual because it comprises two subunits. One is a G protein‐coupled receptor (GPCR), the calcitonin receptor‐like receptor (CLR). This associates with receptor activity‐modifying protein (RAMP) 1 to yield a functional receptor for CGRP. However, RAMP1 also associates with the calcitonin receptor, creating a receptor for the related peptide amylin but this also has high affini...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>British Journal of Pharmacology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7083837</comments>
            <pubDate>Wed, 20 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7083837</guid>        </item>
        <item>
            <title>Ambulatory Blood Pressure Monitoring in Patient With Hypnic Headache: A Case Study</title>
            <link>http://www.medworm.com/index.php?rid=7084418&amp;cid=c_51_25_f&amp;fid=32225&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fhead.12066</link>
            <description>(Source: Headache: The Journal of Head and Face Pain)</description>
            <author>Headache: The Journal of Head and Face Pain</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084418</comments>
            <pubDate>Wed, 20 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7084418</guid>        </item>
        <item>
            <title>Migraine After Sneezing: Pathophysiological Considerations, Focused on the Difference With Coughing</title>
            <link>http://www.medworm.com/index.php?rid=7084419&amp;cid=c_51_25_f&amp;fid=32225&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fhead.12060</link>
            <description>We describe a patient who suffered 3 headache attacks after sneezing, each fulfilling criteria of migraine without aura. Sneezing as a specific trigger for migraine has not been described before.
DiscussionThe differential diagnosis of acute headache after sneezing (eg, subarachnoid hemorrhage and reversible cerebral vasoconstriction), and the differences between migraine after sneezing and “benign cough headache” are discussed. We conclude that a pathophysiological association between migraine and sneezing might exist and hypothesize on underlying mechanisms. (Source: Headache: The Journal of Head and Face Pain)</description>
            <author>Headache: The Journal of Head and Face Pain</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084419</comments>
            <pubDate>Wed, 20 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7084419</guid>        </item>
        <item>
            <title>Laughing Headache With Giant Pacchionian Granulations</title>
            <link>http://www.medworm.com/index.php?rid=7084420&amp;cid=c_51_25_f&amp;fid=32225&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fhead.12056</link>
            <description>We report a single case of severe headache, provoked almost exclusively by outbursts of laughing, where venous magnetic resonance imaging revealed the presence of giant Pacchioni granulations in both right and transverse sinuses. Reviewing published cases of laughing headache, we discuss possible mechanisms of pain and the role of giant Pacchionian granulations. (Source: Headache: The Journal of Head and Face Pain)</description>
            <author>Headache: The Journal of Head and Face Pain</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084420</comments>
            <pubDate>Wed, 20 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7084420</guid>        </item>
        <item>
            <title>Radiologically isolated syndrome - incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review</title>
            <link>http://www.medworm.com/index.php?rid=7084454&amp;cid=c_51_25_f&amp;fid=38862&amp;url=http%3A%2F%2Fmsj.sagepub.com%2Fcgi%2Fcontent%2Fabstract%2F19%2F3%2F271%3Frss%3D1</link>
            <description>With increasing availability of magnetic resonance imaging (MRI), there is also an increase in incidental abnormal findings. MRI findings suggestive of multiple sclerosis in persons without typical multiple sclerosis symptoms and with normal neurological findings are defined as radiologically isolated syndrome (RIS). Half of the persons with RIS have their initial MRI because of headache, and some have a subclinical cognitive impairment similar to that seen in multiple sclerosis. Radiological measurements also show a similarity between RIS and multiple sclerosis. Approximately two-thirds of persons with RIS show radiological progression and one-third develop neurological symptoms during mean follow-up times of up to five years. Cervical cord lesions are important predictors of clinical con...</description>
            <author>Multiple Sclerosis</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084454</comments>
            <pubDate>Wed, 20 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7084454</guid>        </item>
        <item>
            <title>Randomized Trial of Supervised Versus Unsupervised Optokinetic Exercise in Persons With Peripheral Vestibular Disorders</title>
            <link>http://www.medworm.com/index.php?rid=7088992&amp;cid=c_51_25_f&amp;fid=32211&amp;url=http%3A%2F%2Fnnr.sagepub.com%2Fcgi%2Fcontent%2Fabstract%2F27%2F3%2F208%3Frss%3D1</link>
            <description>Conclusions. The DVD may be an effective and economical method of integrating OK into VR. However, rehabilitation should be supervised for greater compliance and improvements, particularly for postural stability and psychological state. (Source: Neurorehabilitation and Neural Repair)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Neurorehabilitation and Neural Repair</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7088992</comments>
            <pubDate>Wed, 20 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7088992</guid>        </item>
        <item>
            <title>MKG Provisions Voluntarily Recalls Atlantic Smoked Salmon Due to Possible Health Risk</title>
            <link>http://www.medworm.com/index.php?rid=7083008&amp;cid=c_51_143_f&amp;fid=32632&amp;url=http%3A%2F%2Fwww.fda.gov%2FSafety%2FRecalls%2Fucm340249.htm</link>
            <description>MKG Provisions of Miami, FL is recalling Atlantic Smoked Salmon Batch# 1768 consisting of several brands of products listed below which have the potential to be contaminated with Listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, listeria infection can cause miscarriages and stillbirths among pregnant women. (Source: Food and Drug Administration)</description>
            <author>Food and Drug Administration</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7083008</comments>
            <pubDate>Wed, 20 Feb 2013 00:13:00 +0100</pubDate>
            <guid isPermaLink="false">7083008</guid>        </item>
        <item>
            <title>Headache as a Rare Presenting Symptom of Löfgren’s Syndrome</title>
            <link>http://www.medworm.com/index.php?rid=7084776&amp;cid=c_51_35_f&amp;fid=38281&amp;url=http%3A%2F%2Fwww.consultantlive.com%2Frss-source%2Farticle%2F10162%2F2128874%3FCID%3Drss</link>
            <description>Löfgren’s syndrome is a form of acute sarcoidosis characterized by a triad of symptoms: hilar adenopathy, erythema nodosum, and arthralgias. This case highlights the typical progression of the disease, following a rare presentation. (Source: Consultant Live)</description>
            <author>Consultant Live</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7084776</comments>
            <pubDate>Tue, 19 Feb 2013 12:00:00 +0100</pubDate>
            <guid isPermaLink="false">7084776</guid>        </item>
        <item>
            <title>Headache as a Rare Presenting Symptom of Löfgren Syndrome</title>
            <link>http://www.medworm.com/index.php?rid=7104568&amp;cid=c_51_35_f&amp;fid=38281&amp;url=http%3A%2F%2Fwww.consultantlive.com%2Frss-source%2Farticle%2F10162%2F2128874%3FCID%3Drss</link>
            <description>Löfgren syndrome is a form of acute sarcoidosis characterized by a triad of symptoms: hilar adenopathy, erythema nodosum, and arthralgias. This case highlights the typical progression of the disease, following a rare presentation. (Source: Consultant Live)</description>
            <author>Consultant Live</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7104568</comments>
            <pubDate>Tue, 19 Feb 2013 12:00:00 +0100</pubDate>
            <guid isPermaLink="false">7104568</guid>        </item>
        <item>
            <title>Hysterectomy Association February Newsletter</title>
            <link>http://www.medworm.com/index.php?rid=7079884&amp;cid=c_51_29_f&amp;fid=38858&amp;url=http%3A%2F%2Fwww.hysterectomy-association.org.uk%2Findex.php%2Fnewsletters%2Fhysterectomy-association-february-newsletter%2F</link>
            <description>Welcome to our latest newsletter, we are already six weeks into 2013 and so much is happening.
Before I go any further though I&amp;#8217;d really like to ask for your help and support. Earlier this month I launched a project called &amp;#8216;In My Own Words: Women&amp;#8217;s Experiences of Hysterectomy&amp;#8216; on a website called Kickstarter.
The purpose of the project is to bring together all the stories we have gathered over the years from women having a hysterectomy. We&amp;#8217;d like them to be in just one book for women, just like you, to read and realise that they aren&amp;#8217;t aren&amp;#8217;t stupid for the questions they ask and they aren&amp;#8217;t alone.
But in order to bring this book to life we need to fund the project, which is where Kickstarter comes in. Can you help us?
You&amp;#8217;ll find much ...</description>
            <author>The Hysterectomy Association</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079884</comments>
            <pubDate>Tue, 19 Feb 2013 11:46:16 +0100</pubDate>
            <guid isPermaLink="false">7079884</guid>        </item>
        <item>
            <title>Uganda: Are You Treating Imaginary Malaria Parasites?</title>
            <link>http://www.medworm.com/index.php?rid=7078602&amp;cid=c_51_20_f&amp;fid=33078&amp;url=http%3A%2F%2Fallafrica.com%2Fstories%2F201302190332.html</link>
            <description>[New Vision]Many people attribute common disease symptoms such as a fever, headache and general body weakness to malaria. Without a confirmed diagnosis of the suspected disease, they rush to treat themselves with antimalarials of their choice. (Source: AllAfrica News: Malaria)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>AllAfrica News: Malaria</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078602</comments>
            <pubDate>Tue, 19 Feb 2013 06:18:43 +0100</pubDate>
            <guid isPermaLink="false">7078602</guid>        </item>
        <item>
            <title>The efficacy of radiofrequency volumetric tissue reduction of hypertrophied inferior turbinate in allergic rhinitis</title>
            <link>http://www.medworm.com/index.php?rid=7078699&amp;cid=c_51_22_f&amp;fid=33822&amp;url=http%3A%2F%2Fwww.indianjmedsci.org%2Ftext.asp%3F2011%2F65%2F7%2F269%2F107387</link>
            <description>Conclusion: RFVTR is safe and effective in treatment of ITH in allergic rhinitis patients. (Source: Indian Journal of Medical Sciences)</description>
            <author>Indian Journal of Medical Sciences</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078699</comments>
            <pubDate>Tue, 19 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078699</guid>        </item>
        <item>
            <title>Pain referral patterns of the C1‐C3 nerves: Implications for headache disorders</title>
            <link>http://www.medworm.com/index.php?rid=7079698&amp;cid=c_51_25_f&amp;fid=33584&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1002%252Fana.23869</link>
            <description>Abstract
The cervical nerves may play a significant role in primary headache disorders. We reviewed the patterns of pain evoked by stimulation of the first 3 cervical nerves (;C1‐C3) in 10 patients with chronic occipital pain, 6 of whom also had migraine. Stimulation at the C1 level evoked periorbital and frontal pain in 6/6 patients with migraine but evoked occipital or cervical pain in those without migraine. C2 and C3 stimulation resulted in occipital or cervical pain in all patients. The C1 nerve may have an important sensory function in headache disorders that have orbital and frontal pain as a prominent feature. Ann Neurol 2013. (Source: Annals of Neurology)</description>
            <author>Annals of Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079698</comments>
            <pubDate>Tue, 19 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079698</guid>        </item>
        <item>
            <title>Engineering control theory helps create dynamic brain models</title>
            <link>http://www.medworm.com/index.php?rid=7079867&amp;cid=c_51_46_f&amp;fid=31011&amp;url=http%3A%2F%2Fwww.eurekalert.org%2Fpub_releases%2F2013-02%2Fps-ect021913.php</link>
            <description>(Penn State) Models of the human brain, patterned on engineering control theory, may some day help researchers control such neurological diseases as epilepsy, Parkinson's and migraines, according to a Penn State researcher who is using mathematical models of neuron networks from which more complex brain models emerge. (Source: EurekAlert! - Medicine and Health)</description>
            <author>EurekAlert! - Medicine and Health</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079867</comments>
            <pubDate>Tue, 19 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079867</guid>        </item>
        <item>
            <title>Orgasmic Headache Treated with Nimodipine</title>
            <link>http://www.medworm.com/index.php?rid=7083059&amp;cid=c_51_156_f&amp;fid=32407&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fjsm.12093</link>
            <description>Conclusions.We postulated a pathophysiological relationship between OH and migraine, especially with respect to vasoconstriction, and believe that in such cases, nimodipine may be an effective therapy. (Source: The Journal of Sexual Medicine)</description>
            <author>The Journal of Sexual Medicine</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7083059</comments>
            <pubDate>Tue, 19 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7083059</guid>        </item>
        <item>
            <title>Hearing and vestibular disorders in patients with systemic lupus erythematosus.</title>
            <link>http://www.medworm.com/index.php?rid=7092654&amp;cid=c_51_41_f&amp;fid=36840&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2FPubMed%2F23423252%3Fdopt%3DAbstract</link>
            <description>ConclusionsMigraine, SNHL and episodic vertigo are comorbid conditions in patients with SLE, but migraine is not associated with SNHL or vertigo in these patients. However, SNHL and vertigo are associated conditions in SLE, suggesting a common audiovestibular dysfunction.
    PMID: 23423252 [PubMed - as supplied by publisher] (Source: Lupus)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Lupus</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7092654</comments>
            <pubDate>Tue, 19 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7092654</guid>        </item>
        <item>
            <title>Hematopoietic stem cell donation.</title>
            <link>http://www.medworm.com/index.php?rid=7115594&amp;cid=c_51_19_f&amp;fid=37097&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2FPubMed%2F23420184%3Fdopt%3DAbstract</link>
            <description>Authors: Chen SH, Wang TF, Yang KL
    Abstract
    Allogeneic hematopoietic stem cell transplantation is now an important treatment for numerous diseases. Donation of hematopoietic stem cells, either through bone marrow (BM) harvesting or peripheral blood stem cell (PBSC) collection, is a well-established and generally accepted procedure. The BM is aspirated from the posterior iliac crest under spinal or general anesthesia, and common side effects include fatigue and local pain. PBSC collection requires 4-6 days of G-CSF injections and leukapheresis 1-2 times. Common side effects of these procedures include bone pain, fatigue, and headache. The side effects of BM and PBSC collections are mostly transient and well tolerated. Severe adverse events are uncommon in healthy donors. At present...</description>
            <author>International Journal of Hematology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7115594</comments>
            <pubDate>Tue, 19 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7115594</guid>        </item>
        <item>
            <title>Managing and Treating Headache of Cervicogenic Origin</title>
            <link>http://www.medworm.com/index.php?rid=7075235&amp;cid=c_51_35_f&amp;fid=38550&amp;url=http%3A%2F%2Fwww.medical.theclinics.com%2Farticle%2FPIIS0025712512002027%2Fabstract%3Frss%3Dyes</link>
            <description>This article reviews and summarizes the points of contention, historical significance, differential diagnosis, and treatments for CGH. This information will be of benefit to clinicians treating patients with this condition and assist providers in reviewing the literature and treatments for CGH. (Source: Medical Clinics of North America)</description>
            <author>Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7075235</comments>
            <pubDate>Mon, 18 Feb 2013 20:00:30 +0100</pubDate>
            <guid isPermaLink="false">7075235</guid>        </item>
        <item>
            <title>Trigeminal Autonomic Cephalalgias Other than Cluster Headache</title>
            <link>http://www.medworm.com/index.php?rid=7075239&amp;cid=c_51_35_f&amp;fid=38550&amp;url=http%3A%2F%2Fwww.medical.theclinics.com%2Farticle%2FPIIS0025712512002131%2Fabstract%3Frss%3Dyes</link>
            <description>Trigeminal autonomic cephalalgias are short-lasting primary headache disorders associated with autonomic symptoms. Paroxysmal hemicrania is a rare headache disorder similar to cluster headache. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) are unusual headache syndromes typified by a high frequency of severe, brief, unilateral attacks that usually occur in the distribution of the trigeminal nerve. SUNCT is a subtype of SUNA in which both conjunctival injection and tearing are present. SUNA differs from SUNCT in that autonomic symptoms are less prominent. (Source: Medical Clinics of North America)</description>
            <author>Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7075239</comments>
            <pubDate>Mon, 18 Feb 2013 20:00:30 +0100</pubDate>
            <guid isPermaLink="false">7075239</guid>        </item>
        <item>
            <title>Targeted Headache History</title>
            <link>http://www.medworm.com/index.php?rid=7075230&amp;cid=c_51_35_f&amp;fid=38550&amp;url=http%3A%2F%2Fwww.medical.theclinics.com%2Farticle%2FPIIS0025712512002052%2Fabstract%3Frss%3Dyes</link>
            <description>The targeted headache history is paramount in the diagnosis of headache and facial pain. Through placing symptoms in categories, a clear picture of the headache diagnosis will begin to emerge. The physical examination yields no positive findings in most patients with headache. Medication overuse headache is emerging as a common reason for inability to control headaches. (Source: Medical Clinics of North America)</description>
            <author>Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7075230</comments>
            <pubDate>Mon, 18 Feb 2013 20:00:29 +0100</pubDate>
            <guid isPermaLink="false">7075230</guid>        </item>
        <item>
            <title>The Role of the Physical Examination in the Evaluation of Headache</title>
            <link>http://www.medworm.com/index.php?rid=7075231&amp;cid=c_51_35_f&amp;fid=38550&amp;url=http%3A%2F%2Fwww.medical.theclinics.com%2Farticle%2FPIIS0025712512002362%2Fabstract%3Frss%3Dyes</link>
            <description>The most critical element in headache evaluation is the history. The targeted history differentiates primary from secondary headaches and provides a realistic list of conditions associated with secondary headache. Several of these conditions present with specific physical findings, such as papilledema, Horner's syndrome, or a cranial nerve palsy. The targeted physical examination of the patient with headache takes less than 3 minutes. The ability to recognize a few straightforward clinical findings directs the evaluation in the proper direction. (Source: Medical Clinics of North America)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7075231</comments>
            <pubDate>Mon, 18 Feb 2013 20:00:29 +0100</pubDate>
            <guid isPermaLink="false">7075231</guid>        </item>
        <item>
            <title>Factors That Cause Concern</title>
            <link>http://www.medworm.com/index.php?rid=7075233&amp;cid=c_51_35_f&amp;fid=38550&amp;url=http%3A%2F%2Fwww.medical.theclinics.com%2Farticle%2FPIIS0025712512002015%2Fabstract%3Frss%3Dyes</link>
            <description>Headaches can be benign or life threatening but, with careful attention to the details described in this article, the correct diagnosis and treatment can be arrived at in many cases. Modern imaging techniques have taken the guesswork out of many conditions but a high index of suspicion and attention to red flags helps avoid potential adverse outcomes in headache encounters in a high proportion of cases. (Source: Medical Clinics of North America)</description>
            <author>Medical Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7075233</comments>
            <pubDate>Mon, 18 Feb 2013 20:00:29 +0100</pubDate>
            <guid isPermaLink="false">7075233</guid>        </item>
        <item>
            <title>How do we fashion better trials for neurostimulator studies in migraine?</title>
            <link>http://www.medworm.com/index.php?rid=7078793&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F8%2F694%3Frss%3D1</link>
            <description>Numerous investigators make tremendous and respectable efforts so that well-designed and -executed prospective, double-blind, randomized, controlled trials can determine definitively whether therapies of interest are indeed safe and effective. In this issue of Neurology&amp;reg;, Schoenen et al.1 report the results of such a trial conducted at 5 tertiary headache centers in Belgium. They determined whether migraine attacks can be prevented by trigeminal neurostimulation with a supraorbital transcutaneous stimulator: Cefaly. This stimulation device is fashionably designed and its frame resembles a lightweight tiara or sporty sunglasses. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078793</comments>
            <pubDate>Mon, 18 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078793</guid>        </item>
        <item>
            <title>Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial</title>
            <link>http://www.medworm.com/index.php?rid=7078795&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F8%2F697%3Frss%3D1</link>
            <description>Conclusions:
Supraorbital transcutaneous stimulation with the device used in this trial is effective and safe as a preventive therapy for migraine. The therapeutic gain (26%) is within the range of those reported for other preventive drug and nondrug antimigraine treatments.

Classification of evidence:
This study provides Class III evidence that treatment with a supraorbital transcutaneous stimulator is effective and safe as a preventive therapy for migraine. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078795</comments>
            <pubDate>Mon, 18 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078795</guid>        </item>
        <item>
            <title>Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes</title>
            <link>http://www.medworm.com/index.php?rid=7078412&amp;cid=c_51_15_f&amp;fid=33011&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fdom.12073</link>
            <description>ConclusionsOral administration of empagliflozin at doses of 10, 25 or 100 mg once daily over 28 days resulted in significant increases in UGE and reductions in blood glucose compared with placebo, and were well tolerated in patients with type 2 diabetes. (Source: Diabetes, Obesity and Metabolism)</description>
            <author>Diabetes, Obesity and Metabolism</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078412</comments>
            <pubDate>Sun, 17 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078412</guid>        </item>
        <item>
            <title>Meta-Analysis: Evidence of Efficacy Lacking for Pediatric Headache Prophylaxis</title>
            <link>http://www.medworm.com/index.php?rid=7069493&amp;cid=c_51_35_f&amp;fid=38281&amp;url=http%3A%2F%2Fwww.consultantlive.com%2Frss-source%2Farticle%2F10162%2F2128514%3FCID%3Drss</link>
            <description>Topiramate and trazadone showed only limited efficacy in treating pediatric headache. No evidecne was found for flunarizine, pizotifen, propranolol, and valproate, to support their use in this population. How to use this information? (Source: Consultant Live)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Consultant Live</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7069493</comments>
            <pubDate>Sat, 16 Feb 2013 14:00:01 +0100</pubDate>
            <guid isPermaLink="false">7069493</guid>        </item>
        <item>
            <title>Hold the Heparin</title>
            <link>http://www.medworm.com/index.php?rid=7066410&amp;cid=c_51_7_f&amp;fid=34151&amp;url=http%3A%2F%2Fjournals.lww.com%2Fcritpathcardio%2FFulltext%2F2013%2F03000%2FHold_the_Heparin.8.aspx</link>
            <description>We present a case of a young man presenting with headache and dizziness found to have marked hypertension, deepening T-wave inversions, and troponin elevation. Initial concerns were for acute coronary syndrome (ACS); however, before anticoagulant and antithrombotic therapy was instituted, further evaluation with noncontrast computed tomography of the head showed intraventricular hemorrhage. Electrocardiographic T-wave inversions are nonspecific and have a broad differential diagnosis, but ACS is of the highest concern especially in the setting of elevated troponin. However, as in this case, T-wave inversion and troponin elevation have been well described in intracranial bleeds as well, and full evaluation is required for such findings before initiation of therapy for presumed ACS to avoid ...</description>
            <author>Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7066410</comments>
            <pubDate>Fri, 15 Feb 2013 15:02:37 +0100</pubDate>
            <guid isPermaLink="false">7066410</guid>        </item>
        <item>
            <title>Element of the week: lead - video | @GrrlScientist</title>
            <link>http://www.medworm.com/index.php?rid=7066636&amp;cid=c_51_58_f&amp;fid=36473&amp;url=http%3A%2F%2Fwww.guardian.co.uk%2Fscience%2Fgrrlscientist%2F2013%2Ffeb%2F15%2F1</link>
            <description>What do California condors, Beethoven and crime rates share in common?This week's element is lead, which has the atomic number 82 and the symbol Pb. Its symbol comes from the Latin word, plumbum, for lead. Lead rarely occurs in its elemental form in the wild. It is typically found in ores along with copper, and in smaller quantities with zinc and silver. Pure lead is a dense, soft and malleable metal with a lustrous bluish-white colour, although its surface quickly tarnishes to a dull grayish color in air. Lead is widespread and easy to work with, making it a popular material throughout the history of human tool-making. Lead has been used in all sorts of items ranging from a variety of pigments to car batteries and bullets. It was also commonly used in pipes for many hundreds of years, giv...</description>
            <author>Guardian Unlimited Science</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7066636</comments>
            <pubDate>Fri, 15 Feb 2013 10:10:00 +0100</pubDate>
            <guid isPermaLink="false">7066636</guid>        </item>
        <item>
            <title>[In Context] News in brief</title>
            <link>http://www.medworm.com/index.php?rid=7063870&amp;cid=c_51_25_f&amp;fid=36844&amp;url=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flaneur%2Farticle%2FPIIS1474-4422%2813%2970035-8%2Ffulltext%3Frss%3Dyes</link>
            <description>Two studies have aimed to provide a clearer picture of which treatments are most useful for children and adolescents with headache and to investigate why the results of many trials have been negative. In a meta-analysis of randomised trials of prophylactic treatments in patients under 18 years of age (JAMA Pediatr 2013; published online Jan 28. DOI:10.1001/jamapediatrics.2013.508), only two drugs were more effective than placebo for episodic migraine (weighted mean differences in headaches per month −0·71, 95% CI −1·19 to −0·24, for two trials of topiramate; −0·60, −1·09 to −0·11, for one trial of trazodone). (Source: Lancet Neurology)</description>
            <author>Lancet Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7063870</comments>
            <pubDate>Fri, 15 Feb 2013 08:35:40 +0100</pubDate>
            <guid isPermaLink="false">7063870</guid>        </item>
        <item>
            <title>[Case Report] In need of something better than sleep</title>
            <link>http://www.medworm.com/index.php?rid=7063670&amp;cid=c_51_22_f&amp;fid=30418&amp;url=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2812%2961892-3%2Ffulltext%3Frss%3Dyes</link>
            <description>In July, 2010, a 32-year-old woman was refered to us with history of mild fever and headache. She had no other symptoms and signs and initial clinical examination and laboratory tests including chest X-ray and urine analysis were done to find the origin of fever. Results of the examination and laboratory tests were negative, and aseptic meningitis was suspected. Cerebrospinal fluid showed 125 cells (64% neutrophils and 27% lymphocytes) and protein and glucose at 0·57 g/L and 3·28 mmol/l, respectively. (Source: LANCET)</description>
            <author>LANCET</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7063670</comments>
            <pubDate>Fri, 15 Feb 2013 07:45:08 +0100</pubDate>
            <guid isPermaLink="false">7063670</guid>        </item>
        <item>
            <title>Bevacizumab: Headache, hypertension and exacerbation of a wound infection: 3 case reports</title>
            <link>http://www.medworm.com/index.php?rid=7062986&amp;cid=c_51_13_f&amp;fid=33942&amp;url=http%3A%2F%2Fwww.ingentaconnect.com%2Fcontent%2Fadis%2Frea%2F2013%2F00000001%2F00001438%2Fart00026</link>
            <description>(Source: Reactions)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Reactions</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7062986</comments>
            <pubDate>Fri, 15 Feb 2013 05:33:21 +0100</pubDate>
            <guid isPermaLink="false">7062986</guid>        </item>
        <item>
            <title>Acute confusional migraine: is it a distinct form of migraine?</title>
            <link>http://www.medworm.com/index.php?rid=7066318&amp;cid=c_51_49_f&amp;fid=38731&amp;url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fresolve%2Fdoi%3FDOI%3D10.1111%252Fijcp.12094</link>
            <description>ConclusionACM may present as either the only manifestation of a migraine attack or in the context of other migraine forms. ACM should have its own distinct place in the ICHD‐II, may be as a subtype of migraine with complex aura. (Source: International Journal of Clinical Practice)</description>
            <author>International Journal of Clinical Practice</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7066318</comments>
            <pubDate>Fri, 15 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7066318</guid>        </item>
        <item>
            <title>Idiopathic hypertrophic cranial pachymeningitis: a rare but treatable cause of headache and facial pain</title>
            <link>http://www.medworm.com/index.php?rid=7067890&amp;cid=c_51_153_f&amp;fid=32209&amp;url=http%3A%2F%2Fjnnp.bmj.com%2Fcgi%2Fcontent%2Fshort%2F84%2F3%2F354%3Frss%3D1</link>
            <description>Introduction Idiopathic Hypertrophic Cranial Pachymeningitis (IHCP) is a rare disease with pain and compression related cranial nerve dysfunction as main clinical features. The leading diagnostic finding of IHCP consists of diffuse or localised thickening of the dura, which demands appropriate imaging and image interpretation. This case description aims at increasing the awareness for the clinical symptoms and imaging findings of this rare disease to allow prompt diagnosis and treatment initiation. Case description An 82-year-old man presented with recurrent left sided headache and worsening facial pain, which had begun more than 1&amp;nbsp;year ago. Neurological examination at presentation revealed ptosis of the left eye and gaze-induced nystagmus when looking to the left; visual function was...</description>
            <author>Journal of Neurology, Neurosurgery and Psychiatry</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7067890</comments>
            <pubDate>Fri, 15 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7067890</guid>        </item>
        <item>
            <title>GOODYS HEADACHE RELIEF SHOT (Acetaminophen And Caffeine) Liquid [Medtech Products Inc.]</title>
            <link>http://www.medworm.com/index.php?rid=7068675&amp;cid=c_51_13_f&amp;fid=35648&amp;url=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2Flookup.cfm%3Fsetid%3D374df462-aff6-4642-ba6f-e83a278fadcf</link>
            <description>Updated Date: Feb 15, 2013 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))</description>
            <author>DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7068675</comments>
            <pubDate>Fri, 15 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7068675</guid>        </item>
        <item>
            <title>Review: Phosphodiesterase inhibitors for erectile dysfunction in men with severe renal disease</title>
            <link>http://www.medworm.com/index.php?rid=7068754&amp;cid=c_51_13_f&amp;fid=38936&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FNews%2F2013---February%2F15%2FReview-Phosphodiesterase-inhibitors-for-erectile-dysfunction-in-men-with-severe-renal-disease%2F</link>
            <description>Source: Journal of Sexual Medicine
Area: News
 Phosphodiesterase inhibitors are generally well tolerated and effective for treating erectile dysfunction (ED), including in patients with significant comorbidity. A review, published in the Journal of Sexual Medicine, examined the safety and efficacy of phosphodiesterase type 5 inhibitors (PDE5) in adult men with erectile dysfunction and severe renal disease or who had received renal transplants. 
 &amp;#160; 
 The authors reviewed published studies of PDE5 inhibitors in patients receiving dialysis or renal transplants. They reported the following findings: 
 &amp;#160; 
 .&amp;#160;Sildenafil significantly improved erectile function as assessed by the International Index of Erectile Function (IIEF), and 75-85% of patients reported improved erectile func...</description>
            <author>NeLM - News</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7068754</comments>
            <pubDate>Fri, 15 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7068754</guid>        </item>
        <item>
            <title>Republished: Drug-induced valvular heart disease</title>
            <link>http://www.medworm.com/index.php?rid=7068981&amp;cid=c_51_22_f&amp;fid=30435&amp;url=http%3A%2F%2Fpmj.bmj.com%2Fcgi%2Fcontent%2Fshort%2F89%2F1049%2F173%3Frss%3D1</link>
            <description>Drug-induced valvular heart disease (DIVHD) was first described in the 1960s. Initially, associations with ergot derivatives used for migraine prevention, or with anorectic drugs, were described. Drugs used for the treatment of Parkinson&amp;rsquo;s disease and endocrine diseases, like hyperprolactinemia, may also induce VHD. More recently, the use of 3,4-methylendioxymetamphetamine (MDMA, &amp;lsquo;Ecstasy&amp;rsquo;) and benfluorexhave been found to be associated with DIVHD. Although some of these drugs were withdrawn from the market, several cases of patients requiring valve surgery even years after the cessation of therapy have been reported. DIVHD is not infrequent, may be severe, and has been described in association with several drugs. Even after drug cessation, long-term implications of this ...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Postgraduate Medical Journal</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7068981</comments>
            <pubDate>Fri, 15 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7068981</guid>        </item>
        <item>
            <title>Migraine Management Practices Among Pediatricians: A Questionnaire-Based Survey</title>
            <link>http://www.medworm.com/index.php?rid=7069367&amp;cid=c_51_33_f&amp;fid=32760&amp;url=http%3A%2F%2Fcpj.sagepub.com%2Fcgi%2Freprint%2F52%2F3%2F265%3Frss%3D1</link>
            <description>(Source: Clinical Pediatrics)</description>
            <author>Clinical Pediatrics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7069367</comments>
            <pubDate>Fri, 15 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7069367</guid>        </item>
        <item>
            <title>Teriflunomide Efficacy and Safety in Patients with Relapsing Multiple Sclerosis: Results from TOWER, a Second, Pivotal, Phase 3 Placebo-Controlled Study (S01.004)</title>
            <link>http://www.medworm.com/index.php?rid=7078826&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FS01.004%3Frss%3D1</link>
            <description>CONCLUSIONS: Teriflunomide 14mg significantly reduced ARR and 12-week disability progression compared with placebo; 7mg significantly reduced ARR. Teriflunomide has a well-characterized safety profile. These results confirm those of TEMSO and support teriflunomide as a treatment option for patients with RMS.Supported by: Genzyme, a Sanofi company.Disclosure: Dr. Miller has received personal compensation for activities with Acorda Therapeutics, Biogen Idec, GlaxoSmithKline, Merck Serono, Novartis, Nuron Biotech, ONO, Genzyme/Sanofi, Questcor, Teva Neuroscience, and Accordant Health Services. Dr. Miller has received personal compensation for activities in an editorial capacity for Continuum and Continuum Audio. Dr. MIller has received research support from Acorda, Biogen Idec, Genentech, Gen...</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078826</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078826</guid>        </item>
        <item>
            <title>Levetiracetam Related Encephalopathy with Opsoclonus and Triphasics (P01.045)</title>
            <link>http://www.medworm.com/index.php?rid=7078876&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.045%3Frss%3D1</link>
            <description>CONCLUSIONS: There are rare reports of toxic encephalopathy due to levetiracetam. Our case has unique manifestations of opsoclonus with triphasic waves on EEG. There should be high index of suspicion in individuals with renal impairment on stable or even adjusted doses of levetiracetam.Disclosure: Dr. Putta has nothing to disclose. Dr. Talwar has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078876</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078876</guid>        </item>
        <item>
            <title>The Prevalence of Tinnitus in Patients Taking Zonisamide (P01.047)</title>
            <link>http://www.medworm.com/index.php?rid=7078878&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.047%3Frss%3D1</link>
            <description>CONCLUSIONS: Our survey reveals that the prevalence of tinnitus while on zonisamide may be higher than what has previously been reported. There are, however, some limitations to this study. The sample population (29) is small and is representative of only one university's clinic. Confounding variables were not accounted for. It is unknown if there were any other factors that could have caused the tinnitus in these patients.Disclosure: Dr. Maltese has nothing to disclose. Dr. Andriola has received personal compensation for activities with UCB as a speaker. Dr. Zilberman has nothing to disclose. Dr. Spiegel has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078878</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078878</guid>        </item>
        <item>
            <title>Safinamide as an Add-On Therapy to a Stable Dose of a Single Dopamine Agonist: Results from a Randomized, Placebo-Controlled, 24-Week Multicenter Trial in Early Idiopathic Parkinson Disease (PD) Patients (MOTION Study) (P01.061)</title>
            <link>http://www.medworm.com/index.php?rid=7078892&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.061%3Frss%3D1</link>
            <description>CONCLUSIONS: Safinamide 100mg/day met the primary objective of significantly improving motor symptoms, quality of life, and borderline significantly ADL, compared to placebo as add-on to a single DA-agonist. These results confirm the efficacy and good tolerability profile of safinamide, already demonstrated in previous studies. Safinamide is a new treatment option for patients with early PD who show signs of loss of benefit on DA-agonist monotherapy.Supported by: Newron/MerckSerono.Disclosure: Dr. Barone has received personal compensation for activities with Boehringer Ingelheim Pharmaceuticals, Inc., Eisai Inc., GE Healthcare, Merck Serono, Novartis, UCB Pharma, and Lundbeck. Dr. Barone has received research support from Boehringer Ingelheim Pharmaceuticals, Inc. Dr. Fernandez has receive...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078892</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078892</guid>        </item>
        <item>
            <title>Safinamide Add on to L-Dopa: A Randomized, Placebo-Controlled, 24-Week Global Trial in Patients with Parkinson's Disease (PD) and Motor Fluctuations (SETTLE) (P01.062)</title>
            <link>http://www.medworm.com/index.php?rid=7078893&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.062%3Frss%3D1</link>
            <description>CONCLUSIONS: Safinamide 50-100 mg/day met the primary efficacy objective of significantly improving ON time without any increase in troublesome dyskinesia, and there was improvement in multiple secondary efficacy measures. These results confirm the efficacy and good tolerability demonstrated previously in Study 016 at daily doses of 50mg and 100 mg.Supported by: Newron/Merck Serono.Disclosure: Dr. Schapira has received personal compensation for activities with GSK, Orion-Novartis, Teva-Lundbeck, Serono, BI as a consultant. Dr. Schapira has received personal compensation in an editorial capacity for European Journal of Neurology. Dr. Schapira has received research support from BI. Dr. Fox has received personal compensation for activities with Merck Serono and Novartis. Dr. Fox has received ...</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078893</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078893</guid>        </item>
        <item>
            <title>Long-Term Safety of IPX066 Extended-Release Carbidopa-Levodopa Capsules in Patients with Early Parkinson's Disease (P01.064)</title>
            <link>http://www.medworm.com/index.php?rid=7078895&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.064%3Frss%3D1</link>
            <description>CONCLUSIONS: Overall, IPX066 demonstrated a favorable tolerability profile throughout extended dosing in early PD. During open-label administration, the frequency of AEs reported was typical of this population.Supported by: Impax Pharmaceuticals.Disclosure: Dr. Nausieda has received personal compensation for activities with Impax, Novartis, UCB Pharma, and Teva Neuroscience. Dr. Nausieda holds stock and/or stock options in Teva Neuroscience, Phytopharm PLC, and Impax, which sponsored research in which Dr. Nausieda was involved as an investigator. Dr. Nausieda holds stock and/or stock options in Abbott, Bristol-Myers Squibb Company, Celgene, Dow Chemical, Dupont, Durata Therapeutics, Eli Lilly &amp; Company, Gilead, GlaxoSmithKline, Inc., Humana, Impax, Johnson &amp; Johnson, Neogen, Phytop...</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078895</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078895</guid>        </item>
        <item>
            <title>Long-Term Safety of IPX066 Extended-Release Carbidopa-Levodopa Capsules in Patients with Motor Fluctuations in Advanced Parkinson's Disease (P01.065)</title>
            <link>http://www.medworm.com/index.php?rid=7078896&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.065%3Frss%3D1</link>
            <description>CONCLUSIONS: Overall, IPX066 demonstrated a favorable tolerability profile during long-term management of advanced PD. Throughout open-label treatment, the percentage of patients reporting AEs was comparable to those in the original IPX066 trials.Supported by: Impax Pharmaceuticals.Disclosure: Dr. Ellenbogen has received personal compensation for activities with XenoPort, Inc., Teva Neuroscience, Boehringer Ingelheim Pharmaceuticals, Inc., Allergan, Inc., Novartis, GlaxoSmithKline, Inc. and Ipsen. Dr. Nausieda has received personal compensation for activities with Impax, Novartis, UCB Pharma, and Teva Neuroscience. Dr. Nausieda holds stock and/or stock options in Teva Neuroscience, Phytopharm PLC, and Impax, which sponsored research in which Dr. Nausieda was involved as an investigator. Dr...</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078896</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078896</guid>        </item>
        <item>
            <title>Chronic Migraineurs Often Present with Severe Gastric Stasis and Inflammation in the Enteric Autonomic Nervous System (P01.069)</title>
            <link>http://www.medworm.com/index.php?rid=7078900&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.069%3Frss%3D1</link>
            <description>CONCLUSIONS: Inflammatory enteric nervous system changes are seen in the myenteric plexus of the full thickness gastric tissue along with gastric emptying delays in patients with chronic migraine. Sensory and motor abnormalities were also observed indicative of systemic autonomic nervous system involvement in the form of progressive and permanent damage in this condition.Fuller characterizations of gastrointestinal and peripheral manifestations of migraine may lead to new diagnostic and therapeutic approaches.Disclosure: Dr. Kedar has nothing to disclose. Dr. Vedanarayanan has nothing to disclose. Dr. Nikitina has nothing to disclose. Dr. Vig has nothing to disclose. Dr. Kori has received personal compensation for activities with MAP Pharmaceuticals, Inc. Dr. Kori holds stock and/or stock ...</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078900</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078900</guid>        </item>
        <item>
            <title>Intravenous Antiepileptic Medications for Exacerbations of Trigeminal Neuralgia (P01.070)</title>
            <link>http://www.medworm.com/index.php?rid=7078901&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.070%3Frss%3D1</link>
            <description>CONCLUSIONS: IV FOS is effective for acute pain in TN, and was well tolerated. Preliminary data suggest that IV LEV may be an alternate therapy, especially when FOS allergy is present. IV AEDs provide an option in the acute management of TN while definitive therapies are planned. Further investigation is required to better understand the role of these medications.Disclosure: Dr. Merritt has nothing to disclose. Dr. Cohen has received research support from Sepracor. (Source: Neurology)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078901</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078901</guid>        </item>
        <item>
            <title>Deep Brain Stimulation of Posterior Hypothalamus in Treatment of Chronic Medically Refractory Cluster Headache: A Case for Preferential Action on Autonomic Symptoms (P01.071)</title>
            <link>http://www.medworm.com/index.php?rid=7078902&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.071%3Frss%3D1</link>
            <description>CONCLUSIONS: The pathophysiological mechanisms (central vs peripheral) leading to pain and autonomic symptoms in CH are still debated. Our case emphasizes the dichotomy in origins of pain and autonomic symptoms with central hypothalamic involvement leading to autonomic symptoms and trigeminal nerve involvement leading to pain.Disclosure: Dr. Chopra has nothing to disclose. Dr. Klassen has nothing to disclose. Dr. Boes has nothing to disclose. Dr. Stead has received personal compensation for activities with Medtronic, Inc. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078902</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078902</guid>        </item>
        <item>
            <title>Analysis of MAP0004 Subjects with Menstrually Related Migraine vs. Non-Menstrually Related Migraine (P01.072)</title>
            <link>http://www.medworm.com/index.php?rid=7078903&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.072%3Frss%3D1</link>
            <description>CONCLUSIONS: In this post-hoc analysis of a Phase 3 study, MAP0004 was similarly effective and tolerated in treating both MRM and non-MRM.Supported by: MAP Pharmaceuticals, Inc.Disclosure: Dr. Aurora has received personal compensation for activities with GlaxoSmithKline, Inc., Merck &amp; Co., Inc., Ortho-McNeil, Allergan, Inc., MAP Pharmaceuticals, Kyowa, and Neuraleve. Dr. Aurora has received research support from Alexza, Allergan, Inc., GlaxoSmithKline, Inc., Merck, Pfizer, Inc., Ortho-McNeil, MAP pharmaceuticals, Takeda, and Neuraleve. Dr. Lu is an employee of MAP Pharmaceuticals. Dr. Connors has received personal compensation for activities with MAP Pharmaceuticals. Dr. Li has received personal compensation for activities with Merck &amp; Co., Inc., as an employee. Dr. Kellerman has r...</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078903</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078903</guid>        </item>
        <item>
            <title>Cluster Belly: A Variant of Irritable Bowel Syndrome? (P01.073)</title>
            <link>http://www.medworm.com/index.php?rid=7078904&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.073%3Frss%3D1</link>
            <description>CONCLUSIONS: Although all of the patient's symptoms may fall within the spectrum of IBS, the semiology of the recurrent abdominal pain attacks are reminiscent of cluster headache, based on the attack duration, restlessness, periodicity, and selective vulnerability to particular triggers only during attack periods. A subset of patients with IBS may feature similar attack profiles and could suggest the hypothalamus as the central attack generator, akin to cluster headache.Disclosure: Dr. Robbins has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078904</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078904</guid>        </item>
        <item>
            <title>Flunarizine Therapy in Migralepsy (P01.074)</title>
            <link>http://www.medworm.com/index.php?rid=7078905&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.074%3Frss%3D1</link>
            <description>CONCLUSIONS: Flunarizine, either alone, or in combination with Propranolol, was effective in 83% of patients to control the occurrence of seizure during migraine episodes. This finding supports the view that Migralepsy is a part of the spectrum of Migraine headache.Disclosure: Dr. Visvanathan has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078905</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078905</guid>        </item>
        <item>
            <title>No Olfactory Deficit in Episodic Cluster Headache (P01.075)</title>
            <link>http://www.medworm.com/index.php?rid=7078906&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.075%3Frss%3D1</link>
            <description>CONCLUSIONS: No lack of olfactory performance was observed in the patient cohort regarding odor threshold, discrimination, identification or TDI-overall performance. Furthermore no lateralization in nasal chemosensory performance could be identified in side comparison in all domains. This is in contrast to previous findings and pulls CH apart from being a multisensory disorder.Disclosure: Dr. Naegel has nothing to disclose. Dr. Buckanie has nothing to disclose. Dr. Holle has received research support from Gr&amp;uuml;nenthal. Dr. Rosenow has nothing to disclose. Dr. Knake has nothing to disclose. Dr. Diener has received personal compensation for activities with Merck &amp; Co., Inc. and Allergan, Inc. Dr. Diener has received research support from Merck &amp; Co., Inc. and Allergan, Inc. Dr. Ka...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078906</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078906</guid>        </item>
        <item>
            <title>Safety of Onabotulinum Toxin A for the Treatment of Chronic Post-Traumatic Headache in Service Members with a History of Mild Traumatic Brain Injury (P01.076)</title>
            <link>http://www.medworm.com/index.php?rid=7078907&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.076%3Frss%3D1</link>
            <description>CONCLUSIONS: OBA appears to be safe and well tolerated in active duty service members treated for PTH, warranting further studies of efficacy and consistency of effect.Disclosure: Dr. Yerry has nothing to disclose. Dr. Lewis has nothing to disclose. Dr. Finkel has recieved personal compensation for activities with Allergan as a consultant. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078907</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078907</guid>        </item>
        <item>
            <title>A Case of Headache Associated with Transient Neurologic Deficits and CSF Lymphocytosis Followed by Transient Ophthalmologic Symptoms (P01.077)</title>
            <link>http://www.medworm.com/index.php?rid=7078908&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.077%3Frss%3D1</link>
            <description>CONCLUSIONS: This report shows transient ophthalmologic symptoms can also present with transient focal weakness, numbness, and aphasia as neurologic manifestations of HaNDL. Although this syndrome is uncommon, it should be considered as a differential diagnosis when patients present with headache and varied transient neurologic deficits.Disclosure: Dr. Thanaviratananich has nothing to disclose. Dr. Jun has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078908</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078908</guid>        </item>
        <item>
            <title>Demand Valve Oxygen: A Promising New Oxygen Delivery System for the Acute Treatment of Cluster Headache (P01.078)</title>
            <link>http://www.medworm.com/index.php?rid=7078909&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.078%3Frss%3D1</link>
            <description>CONCLUSIONS: Based on a small sample size DVO appears to be an effective acute treatment for CH. All subjects on DVO became headache free. Time to pain freedom was fast (average 12 minutes). DVO was more efficacious than CFO as it provided a faster time to headache response (10 minutes vs 18 minutes) and was more likely to produce pain freedom.Supported by: Unrestricted educational grant from Linde Healthcare, The Linde Group.Disclosure: Dr. Rozen has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078909</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078909</guid>        </item>
        <item>
            <title>Vitamin D Status in Migraine Patients: A Case-Control Study (P01.079)</title>
            <link>http://www.medworm.com/index.php?rid=7078910&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.079%3Frss%3D1</link>
            <description>CONCLUSIONS: We did not find any association between migraine and vitamin D status; also severity of headaches was not related to vitamin D level. Younger people with vitamin D deficiency were more susceptible to migraine.Disclosure: Dr. Zandifar has nothing to disclose. Dr. Zandifar has nothing to disclose. Dr. Masjedi has nothing to disclose. Dr. Banihashemi has nothing to disclose. Dr. Asgari has nothing to disclose. Dr. Manouchehri has nothing to disclose. Dr. Zandifar has nothing to disclose. Dr. Saadatnia has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078910</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078910</guid>        </item>
        <item>
            <title>Investigating the Placebo/Nocebo Responses and the Natural History of the Disease in Patients with Migraine (P01.080)</title>
            <link>http://www.medworm.com/index.php?rid=7078911&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.080%3Frss%3D1</link>
            <description>CONCLUSIONS: Our study shows that in migraineurs a true placebo effect can be distinguished from the natural history effect. This is the first study finding evidence that placebo has a true powerful clinical effect in migraineurs. RCTs in migraine patients should consider this interesting phenomenon in the planning of the study and in evaluating side-effects of the pharmacological treatment.Disclosure: Dr. Rubino has nothing to disclose. Dr. Govone has nothing to disclose. Dr. Savi has nothing to disclose. Dr. De Martino has nothing to disclose. Dr. Vacca has nothing to disclose. Dr. Pinessi has nothing to disclose. Dr. Rainero has nothing to disclose. (Source: Neurology)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078911</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078911</guid>        </item>
        <item>
            <title>Evaluation of the Frequency and the Association of Female Pelvic/Genital Pain and Chronic Headache (P01.081)</title>
            <link>http://www.medworm.com/index.php?rid=7078912&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.081%3Frss%3D1</link>
            <description>CONCLUSIONS: It is important to ask women with chronic headache about sexual pain and, if present, be able to offer a management option.Supported by: In part, by an unrestricted grant from Merck.Disclosure: Dr. Gordon has received personal compensation for activities with Purdue Pharma, Pfizer, Eli Lilly, Jansen Ortho and Allergan. Dr. Lay has received personal compensation for activities with Ortho-McNeil Pharmaceuticals, Merck, and Allergan. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078912</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078912</guid>        </item>
        <item>
            <title>Efficacy of MAP0004 in Treating Severe Migraine Pain (P01.082)</title>
            <link>http://www.medworm.com/index.php?rid=7078913&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.082%3Frss%3D1</link>
            <description>CONCLUSIONS: This analysis indicates that MAP0004 was effective in the acute treatment of severe migraine pain in the Phase 3 clinical trial.Supported by: MAP Pharmaceuticals, Inc.Disclosure: Dr. Kori has received personal compensation for activities with MAP Pharmaceuticals, Inc. Dr. Kori holds stock and/or stock options in MAP Pharmaceuticals, Inc. Dr. Kori has received research support from MAP Pharmaceuticals, Inc. Dr. Connors has received personal compensation for activities with MAP Pharmaceuticals. Dr. Zhou has received personal compensation for activities with MAP Pharmaceuticals, Inc as an employee. Dr. Lu is an employee of MAP Pharmaceuticals. Dr. Borland has received personal compensation for activities with MAP Pharmaceuticals as an employee. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078913</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078913</guid>        </item>
        <item>
            <title>The Comorbidity Burden in Patients with Cluster Headache (P01.083)</title>
            <link>http://www.medworm.com/index.php?rid=7078914&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.083%3Frss%3D1</link>
            <description>CONCLUSIONS: Our findings provide high quality information on the prevalence of comorbidities in a complete sample of all patients with CH seen in a large academic medical system over the course of a decade. They suggest that the burden of comorbidities in cluster headache is high. The comorbidity burden of CH may provide clues to the pathophysiology and clinical course of CH. From a research perspective, information about common comorbidities might point to shared biologic mechanisms that could be exploited for treatment purposes.Disclosure: Dr. Joshi has nothing to disclose. Dr. Loder has received personal compensation in an editorial capacity for British Medical Journal. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078914</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078914</guid>        </item>
        <item>
            <title>Spinning out of Control: The Black Box of Basilar Migraine (P01.084)</title>
            <link>http://www.medworm.com/index.php?rid=7078915&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.084%3Frss%3D1</link>
            <description>CONCLUSIONS: In this study, it appears that triptans were a safe, effective abortive treatment of migraine with basilar features. Based on these data, the FDA mandated triptan package insert contraindication in patients with basilar migraine features, should be reconsidered.Disclosure: Dr. Mathew has nothing to disclose. Dr. Joshi has nothing to disclose. Dr. Sheikh has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078915</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078915</guid>        </item>
        <item>
            <title>Evaluation of Cerebral Hemodynamics of Patients with Chronic Migraine: Effects of the Botulinum Neurotoxin-A (P01.085)</title>
            <link>http://www.medworm.com/index.php?rid=7078916&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.085%3Frss%3D1</link>
            <description>CONCLUSIONS: The PI is a well known indicator of peripheral vascular resistance. Our results suggest that BoNTA treatment may be effective by reducing the resistance in intracranial vascular beds in patients with chronic-migraine.Disclosure: Dr. Akgun has nothing to disclose. Dr. Tasdemir has nothing to disclose. Dr. Yucel has nothing to disclose. Dr. Oz has nothing to disclose. Dr. Ulas has nothing to disclose. Dr. Demirkaya has nothing to disclose. Dr. Kutukcu has nothing to disclose. (Source: Neurology)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078916</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078916</guid>        </item>
        <item>
            <title>Consistency of Migraine Pain Relief after Repeated Administration of MAP0004 (P01.086)</title>
            <link>http://www.medworm.com/index.php?rid=7078917&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.086%3Frss%3D1</link>
            <description>CONCLUSIONS: In this post-hoc analysis, MAP0004 provided consistent migraine pain relief for the 1st, 5th, 15th or the 25th QM assessed over approximately one year.Supported by: MAP Pharmaceuticals, Inc.Disclosure: Dr. Kori has received personal compensation for activities with MAP Pharmaceuticals, Inc. Dr. Kori holds stock and/or stock options in MAP Pharmaceuticals, Inc. Dr. Kori has received research support from MAP Pharmaceuticals, Inc. Dr. Lu is an employee of MAP Pharmaceuticals. Dr. Connors has received personal compensation for activities with MAP Pharmaceuticals. Dr. Li has received personal compensation for activities with Merck &amp; Co., Inc., as an employee. Dr. Kellerman has received compensation for serving on the Board of Directors of Ockham CRO. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078917</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078917</guid>        </item>
        <item>
            <title>Rescue Medication Use during MAP0004 Phase 3 Trial (P01.087)</title>
            <link>http://www.medworm.com/index.php?rid=7078918&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.087%3Frss%3D1</link>
            <description>CONCLUSIONS: In this post-hoc analysis of the double-blind period of a Phase 3 trial, rescue medication use was significantly lower with MAP0004 recipients as compared to placebo.Supported by: MAP Pharmaceuticals, Inc.Disclosure: Dr. Kellerman has received compensation for serving on the Board of Directors of Ockham CRO. Dr. Kori has received personal compensation for activities with MAP Pharmaceuticals, Inc. Dr. Kori holds stock and/or stock options in MAP Pharmaceuticals, Inc. Dr. Kori has received research support from MAP Pharmaceuticals, Inc. Dr. Lu is an employee of MAP Pharmaceuticals. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078918</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078918</guid>        </item>
        <item>
            <title>Poor Carbamazepin Response in Patients with Classical Trigeminal Neuralgia and Polytherapy Treatment Options (P01.088)</title>
            <link>http://www.medworm.com/index.php?rid=7078919&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.088%3Frss%3D1</link>
            <description>CONCLUSIONS: Although carbamazepine alone is described as an effective prophylactic option in NT patients, in this terciary hospital series it was effective in monotherapy for less that 30% of patients. The polytherapy may be necessary for the refractory patients and periciazine should be considered in association with carbamazepine.Disclosure: Dr. Martinez has nothing to disclose. Dr. Nunes has nothing to disclose. Dr. de Vasconcellos has nothing to disclose. Dr. Alvim has nothing to disclose. Dr. da Costa has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078919</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078919</guid>        </item>
        <item>
            <title>Efficacy of Greater Occipital Nerve Block with or without Bupivacaine in Chronic Migraineurs (P01.089)</title>
            <link>http://www.medworm.com/index.php?rid=7078920&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.089%3Frss%3D1</link>
            <description>CONCLUSIONS: Greater occipital nerve block is a safe procedure used for the treatment of migraine headache. In our preliminary data, we did not find any difference in the duration of pain relief after GONB with or without bupivacaine. Prospective studies with larger sample size are needed.Disclosure: Dr. Siddiqui has nothing to disclose. Dr. Caplinger has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078920</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078920</guid>        </item>
        <item>
            <title>Mechanism of Arachnoid Cyst Formation Identified by Positional Headache (P01.090)</title>
            <link>http://www.medworm.com/index.php?rid=7078921&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.090%3Frss%3D1</link>
            <description>CONCLUSIONS: One of the theories behind cyst formation is entrapment of cerebrospinal fluid by a one way/ball-valve mechanism. This case provides a compelling argument that the ball-valve mechanism is the cause for cyst formation and enlargement. Clinically, it may be identified by the presence of a positional headache.Disclosure: Dr. Kuruvilla has nothing to disclose. Dr. Haldal has nothing to disclose. Dr. Gaitanis has nothing to disclose. Dr. Klinge has nothing to disclose. (Source: Neurology)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078921</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078921</guid>        </item>
        <item>
            <title>Auditory Hallucinations Associated with Primary Headache Attacks: A Descriptive Case Series and Literature Review (P01.091)</title>
            <link>http://www.medworm.com/index.php?rid=7078922&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.091%3Frss%3D1</link>
            <description>CONCLUSIONS: Paracusias are an uncommon co-occurrence with headache disorders, most commonly migraine, and usually feature the sound of human voices. The timing of the perceived sounds and the very high prevalence of depression may suggest that paracusias are not a form of migraine aura, and other mechanisms should be considered.Disclosure: Dr. Miller has nothing to disclose. Dr. Grosberg has received personal compensation for activities with Tribute Pharmaceutical and Zogenix. Dr. Grosberg has received research support from Allergan, Inc., Electrocore, and Novartis. Dr. Crystal has nothing to disclose. Dr. Robbins has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078922</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078922</guid>        </item>
        <item>
            <title>Use of ACEI in Migraine Prophylaxis: Why We Don't Look Back? (P01.092)</title>
            <link>http://www.medworm.com/index.php?rid=7078923&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.092%3Frss%3D1</link>
            <description>CONCLUSIONS: ACEI have a lower profile of side effects compared to other blood pressure medications currently used in migraine prophylaxis. The benefits with ACEI recognized in the management of congestive heart failure, hypertension associated with diabetes and secondary stroke prevention maybe can be extrapolated to a younger population. Early initiation of an ACEI in patients with migraine attacks can possibly reduce the incidence of stroke in a population at a higher risk of it later in life.Disclosure: Dr. Delgado has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078923</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078923</guid>        </item>
        <item>
            <title>Pontine Infarction as a Complication of Basilar-Type Migraine Status Migrainosus (P01.093)</title>
            <link>http://www.medworm.com/index.php?rid=7078924&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.093%3Frss%3D1</link>
            <description>CONCLUSIONS: This patient presents a diagnostic dilemma, since her stroke symptoms were not part of her typical aura syndrome and therefore does not fulfill ICHD-2 criteria for migrainous infarction. These restrictions on what constitutes a bona fide migrainous infarction may improve specificity at the expense of sensitivity, potentially underestimating the role of migraine in stroke etiology.Disclosure: Dr. Vollbracht's family owns stock and/or stock options in Allergan, Inc. Dr. Robbins has nothing to disclose. Dr. Kister has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078924</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078924</guid>        </item>
        <item>
            <title>Intrathecal Chemotherapy (Part II): Changes in Procedures and Technique. Evaluation of Results (P01.100)</title>
            <link>http://www.medworm.com/index.php?rid=7078931&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.100%3Frss%3D1</link>
            <description>CONCLUSIONS: There was a low rate of side effects, all minor and with full resolution. The IT-ChT technique here described was safe.Supported by: Scholarship Peruilh-Menvielle, School of Medicine, University of Buenos Aires.Disclosure: Dr. B&amp;aacute;ez has nothing to disclose. Dr. Baez has nothing to disclose. Dr. Kuchkaryan has nothing to disclose. Dr. Tafur Canabal has nothing to disclose. Dr. Igirio Gamero has nothing to disclose. Dr. Gonzalez Roffo has nothing to disclose. Dr. Torres has nothing to disclose. Dr. Caffaro has nothing to disclose. Dr. Campanucci has nothing to disclose. Dr. Hurevich has nothing to disclose. Dr. Casas Parera has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078931</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078931</guid>        </item>
        <item>
            <title>Intrathecal Chemotherapy (Part I): First 100 Sequentials Procedures and Its Acute Complications. Technique and Safety (P01.101)</title>
            <link>http://www.medworm.com/index.php?rid=7078932&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.101%3Frss%3D1</link>
            <description>CONCLUSIONS: The IT-ChT procedure following this technique was safe. We observed immediate minor complications to be aware of at the time of performing the IT-ChT.Supported by: Scholarship Peruilh-Menvielle, School of Medicine, University of Buenos Aires.Disclosure: Dr. Casas Parera has nothing to disclose. Dr. Rudy has received personal compensation for activities with Bristol-Myers Squibb Company. Dr. Cardozo-Oliver has nothing to disclose. Dr. B&amp;aacute;ez has nothing to disclose. Dr. Baez has nothing to disclose. Dr. Horsburgh has received personal compensation for activities with Roche. (Source: Neurology)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078932</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078932</guid>        </item>
        <item>
            <title>The First Reported Successful Treatment of Intractable Burning Pain in Erythromelalgia Using OnabotulinumtoxinA: A Case Report (P01.144)</title>
            <link>http://www.medworm.com/index.php?rid=7078975&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.144%3Frss%3D1</link>
            <description>CONCLUSIONS: This is the first report of successful BoNTA treatment of intractable burning pain in erythromelalgia when conventional treatment failed. The mechanism of action may be the blockage of neurotransmitter release from peripheral nerve, but is not known for certain.Disclosure: Dr. Gerwin has received personal compensation for activities with Pfizer. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078975</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078975</guid>        </item>
        <item>
            <title>Long-Term Efficacy, Safety and Tolerability of Ponesimod in Patients with Relapsing-Remitting Multiple Sclerosis (P01.156)</title>
            <link>http://www.medworm.com/index.php?rid=7078987&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.156%3Frss%3D1</link>
            <description>CONCLUSIONS: Long-term treatment with ponesimod maintained efficacy on clinical and MRI outcomes; efficacy on both measures was re-affirmed in ex-placebo patients. No new safety findings were identified.Supported by: Actelion Pharmaceuticals Ltd.Disclosure: Dr. Freedman has received personal compensation for activities with Bayer, Biogen Idec, Teva, Merck Serono, Novartis, Sanofi, and Celgene. Dr. Freedman's institution has received research support from Bayer Healthcare and Genzyme. Dr. Boster has received personal compensation from Merck Serono, Biogen, Novartis, Sun-Pharma, Roche, Genetech, National MS Society, NIH, and Medtronic for consulting services. Dr. Boster has received research support from Merck Serono, Biogen, Novartis, Actilleon, Sun-Pharma, Roche, Genetech, National MS Soci...</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7078987</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7078987</guid>        </item>
        <item>
            <title>Phase 2 BOLD Extension Study Safety Results for Siponimod (BAF312) in Patients with Relapsing-Remitting Multiple Sclerosis (P01.176)</title>
            <link>http://www.medworm.com/index.php?rid=7079007&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.176%3Frss%3D1</link>
            <description>CONCLUSIONS: Siponimod was well tolerated during the first 12 months of extension, in line with the core trial, and no new safety signals were observed.Supported by: Novartis Pharma AG.Disclosure: Dr. Hartung has received personal compensation for activities with Biogen Idec, Teva Neuroscience, Sanofi-Aventis Pharmaceuticals, Inc., Bayer, Novartis, and Merck Serono. Dr. Selmaj has received personal compensation for activities with Biogen Idec, Genzyme, Ono Pharmaceutical, Novartis, Bayer, Hoffmann LaRoche, Merck, Serono and Synthon. Dr. Li has received personal compensation for activities with Genzyme, Novartis, and Nuron as a consultant. Dr. Li has receved research support from Angiotech, Bayer, Berlex-Schering, Bio-MS, Boehringer-Ingelheim, Centocor, Daiichi Sankyo, Genentech, Hoffmann-L...</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079007</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079007</guid>        </item>
        <item>
            <title>Safety and Tolerability of Orally Administered RPC1063, a Novel S1P1 Receptor Modulator, in Healthy Adult Volunteers, Results of a Phase 1 Study (P01.178)</title>
            <link>http://www.medworm.com/index.php?rid=7079009&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.178%3Frss%3D1</link>
            <description>CONCLUSIONS: RPC1063 was generally well tolerated, with a robust PD effect on lymphocyte counts seen at all doses. The emerging favorable safety and PD profile of RPC1063 support its continued development in patients with MS.Disclosure: Dr. Olson has received personal compensation for activities with Receptos as an employee. Dr. Olson holds stock and/or stock options in Receptos. Dr. Hartung has received personal compensation for activities with Receptos as an employee. Dr. Hartung holds stock and/or stock options in Receptos. Mr. Timony has received personal compensation for activities with Receptos, Inc. as an employee. Mr. Timony holds stock and/or stock options in Receptos, Inc. Dr. Peach has received personal compensation for activities with Receptos Inc. Dr. Peach holds stock and/or ...</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079009</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079009</guid>        </item>
        <item>
            <title>Tolerability and Efficacy of Fingolimod in Clinical Practice (P01.183)</title>
            <link>http://www.medworm.com/index.php?rid=7079014&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.183%3Frss%3D1</link>
            <description>CONCLUSIONS: Fingolimod in clinical practice was discontinued at a higher rate than in clinical trials. Discontinuation was primarily due to adverse events and breakthrough disease. Disease activity was adequately controlled in most patients who continued fingolimod.Disclosure: Dr. Hersh has nothing to disclose. Ms. Hara-Cleaver has received consulting fees or honoraria from Biogen Idec, Novartis, Serono and TEVA. Dr. Rudick has received personal compensation for activities with Biogen Idec, Genzyme Corporation, and Wyeth/Pfizer Inc. Dr. Rudick has received research support from Biogen Idec. Dr. Cohen has received personal compensation for activities with Biogen Idec, Eli Lilly &amp; Company, Novartis, and Vaccinex.  Dr. Cohen's institution has received research support from Biogen Idec, B...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079014</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079014</guid>        </item>
        <item>
            <title>Steroid Exposure &amp; Hyperglycemia in Multiple Sclerosis (MS) and Headache (HA) Patients: A Retrospective Chart Review (P01.198)</title>
            <link>http://www.medworm.com/index.php?rid=7079029&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.198%3Frss%3D1</link>
            <description>CONCLUSIONS: Increased hyperglycemia in MS compared to HA patients following a steroid challange has not been previously reported and the mechanism remains uncertain. Future prospective studies are needed to understand the potential hyperglycemic mechanisms including insulin resistance, and assess the impact hyperglycemia has on MS-related neuroinflammation and neurologic recovery.Supported by: ziMS Foundation.Disclosure: Dr. Goldman has recieved personal compensation for activities with Biogen, Acorda, and Novartis. Dr. Koenig has nothing to disclose. Dr. Yeamans has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079029</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079029</guid>        </item>
        <item>
            <title>Presenting Symptoms for the Identification of Acute Stroke and Transient Ischemic Attack in the Emergency Department (P01.241)</title>
            <link>http://www.medworm.com/index.php?rid=7079072&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.241%3Frss%3D1</link>
            <description>CONCLUSIONS: Whether the Patients were diagnosed as definite stroke or not was significantly associated with presenting symptoms of our UTPS code system. The proper selection of presenting symptom for assessment tool used by emergency department staff may be important to improve its performance in acute stroke response system.Disclosure: Dr. Cho has nothing to disclose. Dr. Baek has nothing to disclose. Dr. Yu has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079072</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079072</guid>        </item>
        <item>
            <title>Acute Stroke in Young Women Taking Phentermine (P01.249)</title>
            <link>http://www.medworm.com/index.php?rid=7079080&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.249%3Frss%3D1</link>
            <description>CONCLUSIONS: We present here two patients with mild underlying cerebrovascular risk factors who presented with acute stroke after taking diet pills containing phentermine. The public should be aware of the possible association between stroke and phentermine. More long-term outcomes research is necessary to understand the safety of phentermine-containing diet pills. Patients with cerebrovascular risk factors should be cautious about using Phentermine containing diet pills.Disclosure: Dr. Smit has nothing to disclose. Dr. Cutting has received personal compensation for activities with F1000. Dr. Conners has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Song has received personal compensation in an editorial capacity for serving as Advocacy Editor for AAN.com. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079080</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079080</guid>        </item>
        <item>
            <title>Abulia in a Concussed Athlete (P01.261)</title>
            <link>http://www.medworm.com/index.php?rid=7079092&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.261%3Frss%3D1</link>
            <description>CONCLUSIONS: While abulia is not a common symptom of sports related concussion, this case illustrates an interesting presentation of frontal lobe injury resulting in lack of emotion, apathy, and decreased motivation. It is important to recognize that in addition to the classic symptoms of sports concussions, less common symptoms exist such as impulsivity, depression, insomnia, and in this case, abulia.Disclosure: Dr. Madey has nothing to disclose. Dr. Williams has nothing to disclose. Dr. Bodle has nothing to disclose. Dr. Williams has nothing to disclose. Dr. Lehman has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079092</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079092</guid>        </item>
        <item>
            <title>Risk Factors for Post-Traumatic Headaches after Sport-Related TBI in a Pediatric Subspecialty Clinic Population (P01.264)</title>
            <link>http://www.medworm.com/index.php?rid=7079095&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.264%3Frss%3D1</link>
            <description>CONCLUSIONS: Careful risk factor assessment may help to identify patients more likely to develop persistent PTHA who would benefit from early pediatric neurology clinic referral and intervention.Supported by: The Morris A. Hazan 2011-2012 Friends Fellowship, Child Neurology Foundation, Today and Tomorrow's Children Fund, UCLA BIRC.Disclosure: Dr. Choe has nothing to disclose. Dr. Fischer has nothing to disclose. Dr. Yudovin has nothing to disclose. Dr. McArthur has nothing to disclose. Dr. Giza has received personal compensation for activities with Medical Education Speakers Bureau and Medicolegal consultation. (Source: Neurology)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079095</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079095</guid>        </item>
        <item>
            <title>Autonomic Nervous System Dysfunction in Concussion (P01.265)</title>
            <link>http://www.medworm.com/index.php?rid=7079096&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.265%3Frss%3D1</link>
            <description>CONCLUSIONS: These findings suggest that: 1) ANS dysfunction is a common and previously unrecognized cause of 'dizziness' following concussion; 2) abnormalities can be identified on standard autonomic testing; 3) abnormal adrenergic function is the primary cause of autonomic findings; 4) ANS impairment is a potential biomarker for concussion; and 5) this novel finding has therapeutic implications for patients reporting dizziness following concussion.Disclosure: Dr. Goodman has nothing to disclose. Dr. Vargas has received personal compensation for activities with Merck &amp; Co., Inc. as a speaker. Dr. Dodick has received personal compensation for activities with Allergan, Inc., Pfizer Inc, Merck &amp; Co., Inc., Coherex, Ferring, Neurocore, Neuralieve, Neuraxon, NuPathe Inc., MAP Pharmaceu...</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079096</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079096</guid>        </item>
        <item>
            <title>Onabotulium Toxin Type A (Botox@) in the Treatment of Chronic Post Traumatic Headache Related to Sports Concussion: A Case Report (P01.269)</title>
            <link>http://www.medworm.com/index.php?rid=7079100&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP01.269%3Frss%3D1</link>
            <description>CONCLUSIONS: Onabotulinum Toxin Type A may be an effective treatment in very carefully selected concussed athletes with prolonged headache symptoms. Further research into proper patient selection, long term outcome, return to play and risk of future concussion are needed.Disclosure: Dr. Conidi has received personal compensation for activities with Allergan, Inc. and Forest. Dr. Conidi has received research support from Allergan, Inc. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079100</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079100</guid>        </item>
        <item>
            <title>Pseudo-Hyperdense Middle Cerebral Artery in HSV Encephalitis (P02.025)</title>
            <link>http://www.medworm.com/index.php?rid=7079146&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP02.025%3Frss%3D1</link>
            <description>CONCLUSIONS: A hyperdense middle cerebral artery 'sign' can be associated with acute thrombus1, but several conditions (including encephalitis related cerebral edema) can give the appearance of a 'pseudo'-hyperdense MCA 'sign'.2 REFERENCES 1. Barber PA, Demchuk AM, Hudon ME, Pexman JH, Hill MD, Buchan AM. Hyperdense sylvian fissure MCA &quot;dot&quot; sign: A CT marker of acute ischemia. Stroke. 2001 Jan;32(1):84-8. 2. Jha B, Kothari M. Pearls &amp; oy-sters: hyperdense or pseudohyperdense MCA sign: a Damocles sword? Neurology. 2009 Jun 9;72(23):e116-7.Disclosure: Dr. Kenmuir has nothing to disclose. Dr. Totoraitis has nothing to disclose. Dr. Jovin has received personal compensation for activities with Covidien, Concentric Medical Inc., Stryker Consulting, and Silk Road Medical. Dr. Jovin has recei...</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079146</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079146</guid>        </item>
        <item>
            <title>A Case Report of Dihydroergotamine Administration for Status Migrainosus in a Patient on Longstanding Citalopram Causing a Fatal Reversible Cerebral Vasoconstriction Syndrome (RCVS) (P02.027)</title>
            <link>http://www.medworm.com/index.php?rid=7079148&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP02.027%3Frss%3D1</link>
            <description>CONCLUSIONS: We report this case report of fatal RCVS of a patient on long standing citalopram who developed this after being administered Dihydroergotamine for status migrainosus. As this is thought to be a self-limiting in terms of clinical features. However, some patients may have more severe focal neurologic symptoms and signs, including ischemic or hemorrhagic strokes as described in our patient.Disclosure: Dr. Asi has nothing to disclose. Dr. Gomes has nothing to disclose. Dr. Dani has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079148</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079148</guid>        </item>
        <item>
            <title>Risk Factors for Cerebral Venous Sinus Thrombisis in the past Five Years at Hahnemann University Hospital (P02.036)</title>
            <link>http://www.medworm.com/index.php?rid=7079157&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP02.036%3Frss%3D1</link>
            <description>CONCLUSIONS: In our case series 83% of patients had at least one risk factor. In the largest case series, a risk factor was identified 80% of the time. Headache was the most common presenting symptom of CVST. 60% of our patients presented with headache as their chief complaint, which is consistent with the largest case series where 70% of patients presented with a headache. Although papilledema is often thought to be a common finding, only 13% of our patients had this finding. However, in the largest case series to date 30% of people had papilledema. CVST needs to be considered in the differential diagnosis of headaches even in the absence of papilledema.Disclosure: Dr. Fayyaz has nothing to disclose. Dr. Venkatesh has nothing to disclose. Dr. Koenigsberg has nothing to disclose. (Source: ...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079157</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079157</guid>        </item>
        <item>
            <title>Case Series: Eosinophilic Vasculitis Isolated to the Central Nervous System (P02.053)</title>
            <link>http://www.medworm.com/index.php?rid=7079174&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP02.053%3Frss%3D1</link>
            <description>CONCLUSIONS: To our knowledge, these are the only two cases of non-granulomatous eosinophlic vasculitis isolated to the CNS. No etiology for the vasculitic process has yet been identified. Spontaneous resolution without recurrence with corticosteroid therapy may suggest an environmental epitope with immune reaction as the cause.Disclosure: Dr. Wright has nothing to disclose. Dr. Lewis has nothing to disclose. Dr. Noble has nothing to disclose. Dr. Vonsattel has nothing to disclose. Dr. Khandji has nothing to disclose. Dr. Sommerville has nothing to disclose. Dr. Wright has received personal compensation for activities with Abali, Milne and Faegre, Baker, Daniels, Merck and the NIH. Dr. Wright has received royalty payments from UpToDate. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079174</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079174</guid>        </item>
        <item>
            <title>A Novel Mutation in the Mitochondrial DNA Cytochrome B Gene (MTCYB) in a Patient with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke like Episodes Syndrome (P02.088)</title>
            <link>http://www.medworm.com/index.php?rid=7079209&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP02.088%3Frss%3D1</link>
            <description>CONCLUSIONS: This case demonstrates that MTCYB must be included in the already long list of mitochondrial DNA genes that have been associated with the MELAS phenotype.Supported by: Grant from the National Institutes of Health (HD32062) and by the Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF). PGR is supported by a postdoctoral fellowship from Ministerio de Educacion y Ciencia, Spain.Disclosure: Dr. Emmanuele has nothing to disclose. Dr. Sotiriou has nothing to disclose. Dr. Gutierrez Rios has nothing to disclose. Dr. Ganesh has nothing to disclose. Dr. Ichord has nothing to disclose. Dr. Foley has nothing to disclose. Dr. Akman has nothing to disclose. Dr. DiMauro has received personal compensation in an editorial capacity for MedLink Neurology. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079209</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079209</guid>        </item>
        <item>
            <title>Utilization and Outcomes of Cranial Computed Tomography in a Pediatric Population (P02.097)</title>
            <link>http://www.medworm.com/index.php?rid=7079218&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP02.097%3Frss%3D1</link>
            <description>CONCLUSIONS: Cranial CT scans performed in children are often normal, and findings infrequently change management in patients presenting with seizures, head trauma, and headache. Therefore, it may be safer to consider observation or MRI as alternatives to cranial CT imaging and its associated radiation risks, especially for certain presentations, such as seizure and headache, for which CT is low yield.Disclosure: Dr. Gardner has nothing to disclose. Dr. Hess has received personal compensation in an editorial capacity for the American Journal of Neuroradiology and the Public Library of Science. Dr. Josephson has received personal compensation in an editorial capacity for Annals of Neurology, Journal Watch Neurology, and Contiuum. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079218</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079218</guid>        </item>
        <item>
            <title>Ictal Vasoconstriction of the Left Middle Cerebral Artery on Magnetic Resonance Angiography in Pediatric Confusional Migraine: A Case Series of Five Patients (P02.098)</title>
            <link>http://www.medworm.com/index.php?rid=7079219&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP02.098%3Frss%3D1</link>
            <description>CONCLUSIONS: Our cases demonstrate vasoconstriction in the L MCA territory during a confusional migraine. Vasoconstriction has also been described in some case reports of hemiplegic migraines, lending further credence to the relationship between hemiplegic and confusional migraines. These cases reinforce the role of neurovascular changes in the pathophysiology of migraines.Disclosure: Dr. Spencer has nothing to disclose. Dr. Schomer has nothing to disclose. Dr. Minster has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079219</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079219</guid>        </item>
        <item>
            <title>A Pediatric Case of Reversible Cerebral Vasoconstriction Syndrome: Complexity of Diagnosis Amidst Co-Morbid Anxiety and Depression (P02.099)</title>
            <link>http://www.medworm.com/index.php?rid=7079220&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP02.099%3Frss%3D1</link>
            <description>CONCLUSIONS: RCVS has only rarely been reported in children and only once in a girl. Our case highlights the importance of considering RCVS when a child presents with severe sudden headache, even in the setting of chronic headaches. With the increased use in children of medications such as triptans and SSRIs, which are risk factors for RCVS, the incidence of RCVS in this population may also rise.Disclosure: Dr. Segal has nothing to disclose. Dr. Bain has nothing to disclose. Dr. Amin has nothing to disclose. Dr. Monoky has nothing to disclose. Dr. Thompson has nothing to disclose. (Source: Neurology)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Sponsor Message:&lt;/i&gt;&lt;/b&gt; Have a look at &lt;a href=&quot;http://www.theneurologydaily.com&quot;&gt;The Neurology Daily&lt;/a&gt;, the new neurology portal driven by MedWorm, with all the latest neurology news and research updated daily.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079220</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079220</guid>        </item>
        <item>
            <title>Correlation of Atrial Septal Defect Size as Measured by Intracardiac Echocardiography and Transcranial Doppler Ultrasound in Children and Young Adults (P02.102)</title>
            <link>http://www.medworm.com/index.php?rid=7079223&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP02.102%3Frss%3D1</link>
            <description>CONCLUSIONS: Curtain result on TCD bubble studies is associated with significantly larger ASDs and other cardiac abnormalities in children and young adults.Disclosure: Dr. Doan has nothing to disclose. Dr. Barreto has nothing to disclose. Dr. Fulep has nothing to disclose. Dr. Bui has nothing to disclose. Dr. Butler has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079223</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079223</guid>        </item>
        <item>
            <title>Bilateral, Symmetrical, Linear Enhancement of the Deep White Matter in a Radial Distribution on Brain MRI Is an Identifiable Signature of Primary Angiitis of the Central Nervous System (PACNS) (P02.108)</title>
            <link>http://www.medworm.com/index.php?rid=7079229&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP02.108%3Frss%3D1</link>
            <description>CONCLUSIONS: The presence of diffuse linear enhancement on gadolinium-contrasted study in a radiating fashion on brain MRI may be a diagnostic signature of PACNS.Disclosure: Dr. Ganta has nothing to disclose. Dr. Khalid has nothing to disclose. Dr. Levin has received personal compensation for activities with Serono, TEVA and Biogen-Idec as a speaker and Gerson Lehman Group as a consultant. Dr. Wood has nothing to disclose. (Source: Neurology)</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079229</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079229</guid>        </item>
        <item>
            <title>Atypical Cerebrospinal Fluid Findings in Neuromyelitis Optica Relapse Mimicking Meningitis (P02.143)</title>
            <link>http://www.medworm.com/index.php?rid=7079268&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP02.143%3Frss%3D1</link>
            <description>CONCLUSIONS: Relapses in NMO may be associated with severe CSF pleocytosis mimicking the profile of bacterial CNS infection.Disclosure: Dr. Vargas has received research support from the National MS Society and Biogen Idec. Dr. Gauthier has received personal compensation for activities with Teva, Genzyme, and Biogen Idec. Dr. Gauthier has received research support from Biogen Idec and Novartis. Dr. Nealon has received personal compensation for activities with Biogen Idec and Serono, Inc. Dr. Vartanian has received personal compensation for activities with Biogen Idec, Genzyme Corporation, and Teva Neuroscience. Dr. Vartanian has received research support from Teva Neuroscience. Dr. Perumal has received personal compensation for activities with Teva Neuroscience and Biogen Idec. (Source: Neu...</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079268</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079268</guid>        </item>
        <item>
            <title>Tonabersat, a Novel Investigational Anti-Seizure Drug, Inhibits Seizures in Models of Generalized Epilepsy (P02.209)</title>
            <link>http://www.medworm.com/index.php?rid=7079339&amp;cid=c_51_25_f&amp;fid=32262&amp;url=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F80%2F1_MeetingAbstracts%2FP02.209%3Frss%3D1</link>
            <description>CONCLUSIONS: Tonabersat displayed a robust anti-seizure profile with a high TI in animal models. Its ability to prevent seizure spread in models of generalized epilepsy strongly suggests a therapeutic potential for generalized tonic-clonic seizures, complex partial seizures secondarily generalized, and/or POS.Supported by: Upsher-Smith Laboratories, Inc.Disclosure: Dr. Blower has received personal compensation for activities with Proximagen Ltd. (wholly owned subsiderary of Upsher-Smith Laboratories Inc. of the U.S.), to Cardiokine Inc. (wholly owned subsiderary of Cornerstone Therapeutics Inc. of the U.S. ) and to H. Lundbeck A/S of Denmark as a consultant. Dr. Blower has received compensation for serving on the Board of Phytopharm Ltd. of U.K. Dr. Blower has holds stock and/or stock opti...</description>
            <author>Neurology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=7079339</comments>
            <pubDate>Thu, 14 Feb 2013 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">7079339</guid>        </item>
    </channel>
</rss>
